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CHAPTER I 
INTRODUCTION 
Experimental carcinogenesis in hamster buccal pouch was 
first described by Salley (1954) who demonstrated that 
squamous cell carcinoma can be induced by repeated application 
of a chemical carcinogen such as 7,12-
dimethylbenz (a) anthracene (DMBA) <1>. The two-stage mechanism, 
defined as initiation and promotion, by Berenblum and Shubik 
(1947), are independent components of carcinogenesis and was 
originally demonstrated in mouse skin where, after a 
subcarcinogenic dose of polycylic hydrocarbons was applied, 
macroscopically evident tumors could be induced to develop by 
subsequent application of croton oil <6>. This two-stage 
mechanism is composed of a specific and irreversible 
initiation phase in which normal cells are converted to latent 
tumor cells that lie dormant until stimulated in the promoting 
phase, requiring long-continued administration of large doses 
of a non-carcinogenic agent such as croton oil, to become 
1 
2 
morphologic tumors. The concept recently has acquired wider 
validity and it has been shown to operate effectively for 
hamster pouch epithelial carcinogenesis with the use of 
phorbol ester, 12-0-tetradecanoylphorbol-13-acetate (TPA) as 
the promoting agent. 
The major recent advance in the molecular basis of 
carcinogenesis has been in the field of oncogenes, which are 
genes with a proven cancer association. A small group of 
genes, known as ras, is an ubiquitous eukaryotic gene family. 
It was derived from the words "rat sarcoma" because these 
genes were first identified as the transforming properties of 
the Harvey and Kirsten strains of rat sarcoma viruses. 
Ras oncogenes have been implicated in the development of 
a variety of spontaneous human neoplasias (approximately 10-
15%) and in virally and chemically induced tumors <105> 
Identification of the activated c-rasH gene by Balmain, in the 
majority of skin papillomas induced by a single application 
of the carcinogen DMBA and promoted by treatment with TPA 
provides for the biologic evidence that ras genes can be 
activated during the early stages of tumor development <128> 
Many investigations have also shown a mutational event 
in the induction of skin carcinomas in mice by DMBA and 
Phorbol esters involving the specific activation of H-ras-1 
oncogene by A (adenine) --> T (thymine) mutation in the second 
base of codon 61 <130> It is now generally agreed that 
chemically induced carcinogenic process passes through the 
3 
steps of preneoplastic, premalignant and malignant changes 
involving the sequential evolution of genotypically initiated 
cells to phenotypically altered cells. 
since no such two-stage chemical carcinogenesis with a 
single dose of carcinogen, followed by multiple doses of 
promoter has been demonstrated in hamster pouch model for oral 
carcinogenesis, this investigation was undertaken to study 
morphologic events and phenotypes in cells of hamster buccal 
pouch epithelium initiated by the application of a single dose 
of chemical carcinogen DMBA and followed by multiple doses of 
promoter TPA. Hypothetically, the initiation of chemical 
carcinogenesis that occurs in the epithelial cells, might have 
the inheritable character due to alterations of the nucleotide 
biochemical properties by DNA adducts formation or aberrant 
alkylation of nucleotide components induced by single dose 
DMBA. Initiation event may be reflected during expansion of 
the phenotypes by TPA that enhances the nuclear DNA 
macromolecular synthesis and 
population of the initiated cells. 
therefore increases the 
However, this phenotypic 
expression could not be accomplished alone by promoter TPA in 
the absence of initiation. 
An additional objective is to detect some oncogenic 
proteins, ras p21, transforming growth factor alpha and 
epidermal growth factor recepter which are relevant to the 
phenotypes of neoplastic epithelium by using 
immunohistochemical methods. By the thirteenth week, we are 
4 
able to demonstrate de nova changes of atypia/dysplasia in the 
epithelium. 
Further evidence suggestive of oncogenic properties is 
noted by overexpression of ras p21 protein, tr an sf arming 
growth factor alpha (TGF- Ol) , and epidermal growth factor 
receptor (EGF-R). 
An additional semiquantitative evaluation of Langerhans 
cells is also investigated. Although Langerhans cells are 
unreactive with S-100 and LN-3 antibodies in normal hamster 
pouch epithelium and those treated with DMBA/TPA, they are 
reactive in human oral gingival epithelium as evaluated by the 
same immunohistochemical methods. 
CHAPTER II 
REVIEW OF THE LITERATURE 
(A). Hamster Model in Carcinogenesis 
Experimental carinogenesis in hamster buccal pouch 
was first described by Salley (1954) who reported that 
O. 5% DMBA was the most effective carcinogen, and that the 
first tumor appeared after seven weeks of painting the 
hamster pouch thrice-weekly <1>. During the first two 
weeks, there was an inflammatory phase with necrosis and 
sloughing of the pouch epithelium. This was followed by 
healing and shrinkage of pouch mucosa. The epithelial-
stromal wall of the pouch passed through four 
histologically distinct stages before the appearance of 
overt neoplasms, there being 1) inflammation, 2) 
degeneration and necrosis, 3) regeneration and 4) 
hyperplasia <2>. 
This model had been subsequently defined by Morris 
5 
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and Shklar and associates in the early sixties. Morris 
(1961) showed that the pouch epithelium of old hamsters 
was more resistant to the action of DMBA than that of 
young animals and that five weeks appeared to be the 
optimum age of hamsters for starting studies in 
experimental carcinogenesis, from the standpoint of ease 
of manipulation and tumor production. A 0.5% solution 
of DMBA in acetone painted on hamster pouch produced 
maximum tumor yield and minimum latent period and no loss 
of animals due to toxicity <3>. 
A shorter latent period was required for tumor 
development in animals when exposed to a carcinogen three 
times per week than in those receiving the carcinogen 
twice-weekly <3>. Morris and Reiskin (1966), reported 
that painting the pouch three times a week for 4 weeks 
resulted in tumor development in all animals, but that 
painting for less than 3 weeks failed to produce any 
tumors <4>. 
Salley <2•5> also discovered that heavy mineral oil 
solvent reduced the latent period for tumor production 
from 7 weeks to 4 1/2 weeks. The reason for the reduced 
latent period probably was due to the sustained tissue 
penetration of carcinogen rather than a true co-
carcinogenic action <6• 7> 
Morris et al (1961), also confirmed that the 
concentration of 0.5% DMBA in heavy mineral oil was the 
7 
best concentration for rapid induction of epithelial 
tumors in the hamster buccal pouch <3>. 
Hamster buccal pouch is an excellent model for oral 
squamous cell carcinoma, because of the consistent, 
predictable time patterns of tumor development, as well 
as the preceding premalignant/precancerous lesions. <5> 
(B). Initiation and Promotion (Two-stage Mechanism) 
Berenblum•s early studies (9, 10) in mouse skin 
carcinogenesis suggested that induction of carcinogenesis 
consisted of three phases: a) the preneoplastic phase or 
precarcinogenic action, b) conversion into the wart stage 
or epicarcinogenic action, and c) the malignant 
transformation or metacarcinogenic action. Additionally, 
Berenblum demonstrated that croton oil when used with a 
very dilute (0.05%) solution of benzopyrene (BP), could 
cause marked augmentation of carcinogenesis when applied 
weekly to the skin of mice. Subsequently, Mottram ( 1944) 
showed that a single application of BP was adequate to 
induce tumors in epithelium when used in croton oil <11 • 
12) Based upon Mottram' s findings, Berenblum (1947) 
concluded that initiation process represents a sudden and 
an irreversible change in a small fragment of cells of 
the treated area, and giving rise to isolated "latent 
tumor cells", apparently indistinguishable, 
8 
morphologically, from the surrounding non-neoplastic 
cells <6>. The presence of these latent tumor cells is 
only demonstrable by subsequent promoting action, which 
converts them into morphologic tumors. 
This interpretation of initiation and promotion of 
chemical carcinogenesis accorded well with that of 
Friedewald' s and Rous' s concepts <13> of an "Initiating 
Process" responsible for the conversion of certain normal 
cells into latent tumor cells, and a "Promoting Process" 
whereby these latent tumor cells were made to develop 
into growing tumors. Berenblum's subsequent studies in 
1949 also showed that the time interval between 
initiation and promotion was extended to almost a year 
( 43 weeks) from the usual one to two weeks <14 , 15> 
However, there was no change in the mean latent period, 
after the beginning of promotion. The result also 
supported the concept that the "latent tumor cells" 
induced by single application of a carcinogen represents 
an irreversible change from normal cells. 
Another quantitative approach to chemical 
carcinogenesis in mouse skin was analyzed by Berenblum 
and Shubik (1947) and supported the idea that the 
initiator determines the eventual tumor yield (tumors 
induced in proportion to the concentration of the 
initiating agent) and that the promoter determines the 
latent period <16> If the sequence of initiation and 
9 
promotion is reversed, the tumor yield would not occur 
because of the weak carcinogenic action of promoters <17> 
Carcinogenesis as proposed by Berenblum and 
Weinstein <6• 14• 15 • 16• 18> is probably a two-stage mechanism 
consisting of a specific and irreversible initiating 
phase in which normal cells are converted to latent tumor 
cells that lie dormant until stimulated in the promoting 
phase to become and progress as morphologic malignant 
tumors. 
Berenblum <19> Colburn and Boutwell <20 > stated that 
initiation requires only a single application of the 
chemical carcinogen to epidermis and is thus a relatively 
rapid process. 
stated that 
Berenblum <14• 15 >, Scribner and suss <21 > 
initiation can produce no apparent 
morphologic alterations in the epidermis. In contrast, 
promotion is a slow process requiring repeated exposure 
to the promoter agent over a latent period of several 
weeks (Berenblum and Shubik 194 7 <6 • 16>, Boutwell 1964 & 
1972 <22• 23>, Stenback et al, 197 4 <24>.) • 
Although small doses of carcinogen can induce tumor 
formation when amplified by a promoter, a single high 
dose of a carcinogen is sufficient to elicit tumor 
formation without subsequent promoter treatment <25 >. The 
action of promotion on tumor formation may be reversible, 
even after benign tumors have formed. This is suggested 
by the fact that discontinuation of promoter treatment 
10 
could result in regression of many of these tumors. 
Moreover, increasing the intervals between promoter 
application beyond the optimal time, greatly reduces or 
eliminates the promoting effect on tumor formation in 
mouse skin (22, 24) In those instances when promoter 
treatment is modified, the initiation-promotion model 
involves the sequential application of, first, a single, 
essentially, non-carcinogenic dose of a carcinogen, most 
commonly DMBA, followed by repetitive application, to the 
same area, of promoting agents (such as the phorbol 
ester, TPA) , which produce only a few tumors when 
applied alone (promoter TPA, alone). 
(C). Biological Aspect of DMBA 
Chemical carcinogens are capable of interacting with 
a wide variety of cellular macromolecules, which usually 
involve the alkylation of nucleophilic (electron-rich) 
groups on nucleic acids or proteins with electrophilic 
(electron-seeking) groups of the carcinogen <26>. 
According to previous studies by Millers (1947), 
Sorof (1969 and 1974), Sarrif (1975) and Litwack (1971), 
the covalent binding of various carcinogens to proteins 
in target tissues has been shown already <27• 28• 29• 3o, 31 
respectively). 
The mechanism of chemical carcinogenesis was origin-
11 
ally proposed by Pullmans (1955) who demonstrated that 
in the presence of oxygen, the key epoxide formation 
involved the K-region of the hydrocarbon ring structure 
(32) It is now generally accepted that conversion of 
polycyclic aromatic hydrocarbon (PAH) to dihydrodiol 
epoxide is the crucial pathway in the formation of 
ultimate carcinogens <33>. 
The dihydrodiol epoxides are the principle DNA 
binding mutagenic and carcinogenic metabolites. 
Therefore, Jerina and Daly (1977) postulated the so-
called "bay region" theory of PAH carcinogenesis <34>. It 
is that, for a compound to be highly mutagenic and 
carcinogenic, "diol epoxide" must be generated in the bay 
region of the PAH molecule formed by the polycyclic 
structures of the molecules. Brookes and Lawley (1964) 
also showed a correlation between DNA binding in mouse 
skin and the carcinogenic potencies of PAH carcinogens 
(35) 
It has been shown that benzo(a)pyrene-DNA (BP-DNA) 
binding in mouse skin in vivo occurs primarily through 
reaction of the anti-stereoisomer of the 7-8 dihydrodiol-
9, 10-epoxide, the bay region dihydrodiol-epoxide 
metabolite of BP, with guanine residues in DNA <~>. A 
chemical carcinogen, DMBA, belongs to the PAH. DMBA 
predictably initiates and promotes cancer formation in 
vivo and in vitro, and is therefore a complete 
12 
carcinogen. 
Recent studies done by Sawicki and Dipple (1983), 
indicated that the binding of DMBA to mouse embryo cell 
DNA involves both the syn- and anti-stereoisomer of the 
3,4- dihydrodiol-1, 2- epoxide and that, in addition to 
reaction with guanine, substantial binding to adenine 
also occurs <37• 38>. 
Anita et al (1983), also identified the fact that, 
by comparing the specific reaction products formed by 
DMBA and BP in mouse skin, there are two major 
differences regarding the products of binding to DNA <39>. 
First, there is a more substantial modification of DNA 
by the syn-stereoisomer of the bay region dihydrodiol-
epoxide of DMBA (40% of total DNA binding in DMBA and 
only about 12% in BP). Second, there is much more 
binding of hydrogen to deoxyadenosine residues when DMBA 
is used (27-48% of total DNA binding in DMBA and less 
than 2-3% in BP). Any one of these differences might 
account for the greater tumor initiating potency 
exhibited by DMBA, which is approximately 20 times more 
potent than is BP <39>. 
Another example of carcinogen-binding protein 
discovered by Sarrif (1975) was the cytosol carcinogen-
binding protein found in mouse skin and mouse liver, 
after treatment with PAH <30>. 
A subsequent study demonstrated by Custer and Sorof 
13 
(1984), was that the amount of a 14000 MW polypetide, 
which is one of the major cytosolic binding proteins in 
liver cells for the hepatic carcinogen, 2-acetyl-
aminofluorene appears to be related to the level of cell 
mitosis and is high in preneoplastic foci in the livers 
of carcinogen-treated rats <40>. 
The DNA base-adducts formation which occur in the 
bay region syn- and anti-dihydrodiol epoxide of DMBA and 
the resultant deoxyadenosine and deoxyguanosine adducts 
in DNA and by other chemical carcinogens may distort the 
helix of DNA. This leads to a mutation-like event, 
during DNA replication past the point of the inter-
calation <41 >. 
As an example, alkylated bases in DNA mispair with 
wrong bases during DNA replication. In this context, 
alkyl-0-6-guanine (0-6 methylguanine) pairs with thymine 
rather than cytosine, and leading to the base transition 
(GC --> AT) type of mutation during the next round of DNA 
replication <42>. This species of 0-6 alkylation of DNA 
guanine residues has been shown to correlate with 
mutagenici ty and carcinogenicity <43>. 
Slago et al (1974), reported several facts about the 
macromolecular synthesis of DMBA-initiated tumorigenesis 
in the mouse model <44 >. They found that a single 
initiating dose (0.05 or 0.10 umole) of DMBA depressed 
DNA synthesis for 24 hours without a subsequent increase, 
14 
and there was no detectable epidermal hyperplasia. Nor 
was RNA or protein synthesis altered <44 >. In contrast, 
at levels of carcinogen which act not only as an 
initiator but also as a complete carcinogen when given 
repetitively, RNA, protein and DNA synthesis were 
stimulated <44>. 
According to Laerum•s and Iversen's studies, it can 
be concluded that carcinogens provoke obvious changes in 
some aspects of the cell kinetics of tissues <45 > These 
include the prolongation of DNA synthesis time, the 
mitotic duration, and a shortening of the cell cycle of 
the cells in the proliferating or growth fraction. 
The epithelial changes in hamster buccal pouch 
carcinogensis induced by DMBA are classified as 
hyperplasia, dysplasia and carcinoma stages. The 
macroscopic and histologic changes observed preceding 
neoplastic development resemble the human premalignant 
conditions of oral mucosa <232>. The histologic changes 
have been classified as hyperplasia with no evidence of 
cellular atypia, and dysplasia which demonstrates a 
variety of atypical features <46>. Santis et al ( 1964) , 
were able to demonstrate the existence of hyperkeratotic 
and dysplastic lesions comparable to that of human oral 
leukoplakia, which is a precancerous lesion <47> 
Mork and Main (1976), used a technique to maintain 
the organotypic morphology of neonatal hamster cheek 
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pouch mucosa and, in 1980, reported their findings on the 
effect of the single application of DMBA in vivo. They 
found that the neonatal hamster cheek pouch explants when 
exposed to o. 05 ug/ml DMBA one to three hours before 
being set-up in vitro, showed severe dysplastic changes 
noted by 21 to 28 days, and they were similar to changes 
seen in human oral premalignancy. By 35 days, in vitro, 
these changes had disappeared and the epithelium returned 
its normal morphology <4B>. The initial irreversible 
change had taken place but required a promoting agent or 
stimulus in order for full neoplastic expression <~>. 
The biological reaction to an initiator such as DMBA 
is dose dependent. However, as Reddy and Fialkow proved, 
by using single application of different doses of DMBA 
on two-stage skin carcinogenesis in BALB/c mice, not only 
does the carcinogen cause initiation in mouse skin 
epidermal cells, but also the dose of carcinogen strongly 
inf lucences the mode of growth of the initiated cells to 
papillomas and progression of these tumors <49> 
This dose-dependency of carcinogen is based on the 
hypothesis made by Scribner et al (1983), that there is 
heterogeneity in papillomas as observed in promoter-
dependent or -independent papillomas. This results from 
carcinogen-induced variatious in the level of initiation 
in target cells interpreted as "low-levels of initiation 
and high-levels of initiation". Their data strongly 
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support the view that the dose of the carcinogen plays 
a critical role in determining which initiated cells will 
progress to malignancy during or after promotion <50> 
(D). Biological Aspect of TPA 
The promoter, 12-0-tetradecanoylphorbol-13-acetate 
(TPA) is a strong inf lammatogenic and hyperplasiogenic 
agent. Also, it can cause the epidermis to mimic tumor 
cells in a reversible manner. Berenblum (1954), 
suggested that the promoting action is essentially a 
process of delayed maturation of epithelum, thereby 
allowing a sufficient number of undifferentiated daughter 
cells to accumulate to form a colony of cells of critical 
size <51 > 
Several investigators, such as Rover a et al <52> and 
Diamond et al (53) 
formation based on 
proposed a mechanism for 
the control of altered 
tumor 
cell 
differentiation. They proposed that tumor promoters 
inhibit terminal cell differentiation in vitro by 
transient blocking of cell differentation that favors 
proliferation of the stem cell population. This could 
lead to amplification of cell populations where the 
potential for malignancy has been initiated by a 
carcinogen but is not yet expressed. Thus, promotion may 
involve at least two components: an inhibition of 
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maturation of basal cells plus their increased 
proliferation <54>. 
TPA, when applied to squamous epithelium affects the 
plasma membrane of cells and can cause a cascade of 
pleiotropic responses. These include an elevation of 
epidermal adenosine 3', 5 1 -monophosphate cyclic AMP <55>, 
stimulation of phospholipid synthesis <56>, increased 
synthesis of prostaglandins (E2) after 10 minutes <57• 58>, 
the induction of orni thine decarboxylase <59• 60• 61> TPA 
also affects more general inductions of gene activation; 
namely, increased RNA, protein, DNA synthesis and cell 
proliferation (62, 63, 64, 65) TPA could also alter the 
morphology of mouse epidermal cells <65>. 
In addition to inflammatory effects of TPA on mouse 
skin that erythema, edema, leukocyte 
infiltration, 
include 
there is also hyperplasia, cell 
dissociation and formation of dark keratinocytes <66• 67> 
The induction and increased number of dark keratinocytes 
by tumor promoters, especially TPA, has been interpreted 
as a good indicator of the promoting action which was 
suggested by Andres et al <6S>. 
It has been demonstrated that the tumor promoting 
phorbol esters produce a number of changes directly in 
cell membrane and can indirectly damage chromatin by 
generating "free oxygen radicals". 
Cerutti (1985) showed that tumor promoters can 
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damage DNA within chromosomes without reacting with it 
directly <69>. They can do this by stimulating cells to 
produce activated forms of oxygens including superoxide 
anion radicals (02-) and hydrogen peroxides (H20 2). This 
reaction is effected by the pentose phosphate pathway 
that requires NADPH oxidase, which reduces oxygen to the 
superoxide anion. 
Tumor promoters, in general, induce free oxygen 
radical release in polymorphonuclear neutrophils and that 
release is inhibited by anti-promoters. Birnboim 
suggested that stimulation of white blood cells with TPA, 
release free radicals which can induce DNA damage in 
other cells <70>. However, this effect can be inhibited, 
for example, by retinoids, which inhibit promotion of 
mouse skin tumors by preventing activated oxygen 
production of neutrophils in response to promoters. 
Similar evidence is that some of the changes in gene 
expression induced by TPA may be due to the effect of 
oxygen radical generation, since induction of ornithine 
decarboxylase required for cell proliferation by TPA, is 
blocked by the anti-oxidant enzyme catalase and 
superoxide dismutase <71 >. 
Furthermore, Cerutti showed that cells that have 
been treated with TPA secrete into the incubating medium 
a destructive clastogenic material that induces the 
chromosomal abnormalities in untreated cells. It is not 
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only responsible for chromosomal damage in the stimulated 
cell itself but also affects the damage to neighboring 
cells <70>. 
The primary action site of the tumor promoting 
phorbol esters has been suggested to be on cell surf ace 
membranes by many investigators <72• 73> Many of the 
pleiotropic effects of tumor promoters, now are thought 
to be due to their ability to activate a calcium and 
phospholipid-dependent enzyme <74• 76> first discovered by 
Nishizuka and his colleagues <75 >, known as protein kinase 
C (PKC). PKC probably serves as a receptor for tumor 
promoters and it has a crucial role in signal 
tranduction for a variety of biologically active 
substances which activate cellular function and 
proliferation. 
Previous studies indicate that PKC catalyzes the in 
vitro phosphorylation of a 40-kd protein in platelets 
<78>, vinculin <79>, myelin basic protein <80 >, and lysine-
rich histones (81) There is evidence that PKC also 
phosphorylates the receptors for epidermal growth factor 
(EGF), insulin and somatomedin <82 • 159>. Those findings 
suggest that PKC is a major initial cellular binding site 
and transducer of the pleiotropic effects of phorbol 
ester tumor promoters, as well as many biologically 
active substances. 
PKC consists of a single polypeptide chain (MW 
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77,000) that appears to be composed of two functionally 
different domains: one is a hydrophobic domain that may 
bind to membranes; the other one is a hydrophilic domain 
that carries the catalytically active center. 
A wide variety of extracellular signals, growth 
factors, hormones and neurotransmitters, through 
interaction with membrane receptors, have repeatedly been 
shown to provoke the breakdown of inositol phospholipids 
by phospholipase C (PLC) in their target tissues and 
activation of PKC <54, 85 • 86• 87>. 
At least three different messenger molecules are 
known to be produced from phosphoinositides:arachidonic 
acid, inositol-1,4,5-triphosphate [Ins(l,4,5)P3 ] or IP3 
and 1, 2-diacylglycerol (DG) • Arachidonate is 
peroxidated by 
respectively, to 
cyclooxygenase and 
form the mediators: 
lipooxygenase, 
prostaglandins, 
thromboxane and leukotrienes. IP3 functions as a second 
messenger to mobolize (Ca++) i, from an intracellular site, 
probably in the endoplasmic reticulum. DG, one of the 
earliest products of signal-induced inositol phospholipid 
breakdown (an essential cofactor for PKC) is a messenger 
that greatly increases the affinity of PKC for calcium 
ion, thereby activating it. 
The effect of growth factors like platelet-derived 
growth factor-PDGF, and vasopressin, which activates PKC 
in mouse Swiss 3T3 cells, results in increased f~rmation 
of DG and IP3 css, 89> • 
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DG operates within the plane of 
the cell membrane to activate PKC, whereas IP3 oscillates 
between plasma membrane and endoplasmic reticulum 
membrane resulting in oscillationally cytosolic calcium 
ion concentration. DG is normally absent from cell 
membranes, but is transiently produced from inositol 
phospholipids in response to extracellular ligand-
receptor signals. Some studies made by Nishizuka and 
Yamanishi et al <75 , 90> indicate that TPA, which has a 
diacylglycerol-like structure, is able to substitute for 
diacylglycerol at extremely low concentrations. In this 
manner, TPA increases the affinity of PKC enzyme for 
calcium to the 10-7 M range, resulting in its activation 
(75, 90) 
Recently, Gainer and Murray ( 1985) , also showed that 
PKC is an important regulator of gap junctional 
permeability in cultured mouse epidermal cells (HEL-37 
cells), and that decreased permeability of the gap 
junction induced by TPA promoter is mediated via 
activation of this calcium-dependent PKC enzyme, which 
directly phosphorylates the gap junctional protein <91>. 
There is convincing evidence that the "metabolic 
cooperation" that occurs between normal epithelial cells 
is eliminated by TPA and it is possible that this is an 
important component of the mechanism of tumor promoter 
(92, 93) Enomoto et al (1985), also reported that, by 
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using a fluorescent dye-transfer method to determine cell 
membrane permeability, the application of tumor promoter 
(TPA) to the cultured BALB/C 3T3 cells promotes the final 
expression of phenotypes of premalignant cells, by 
blocking intercellular protochannel (cell to cell) 
transmembrane communications among these cells with 
adjacent normal cells <94>· These observations suggest 
that tumor promoter-mediated inhibition of cell 
communication might have an important role in the process 
of two-stage carcinogenesis in vivo and in vitro. 
Further study on the expression of tumor promoter-
associated gene product was done by Peter Krieg et al 
(1988). By using the Northern Blot RNA analysis, they 
were able to identify the enhanced expression of transin, 
a secreted protease, which was undetectable in cells of 
normal epidermis, but found only in the basal cells of 
the TPA-treated epidermis. Transin was not detected in 
the nontumor-promoting hyperplastic agent, ethylphenyl-
propiolate (EPP)-treated epidermis <~>. These findings 
suggest that there might be a tumor promoter-associated 
gene expression that could alter the cell phenotypes of 
initiated colonies and offer a selective growth advantage 
for tumor promotion <95> 
(E). Ras p21 Oncogene Protein 
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several human tumor cell lines contain genes that 
can transform NIH 3T3 cells (mouse fibroblasts) into 
malignant cells. Certain genes have been classified as 
members of the ras oncogene family; namely, Ha-ras, Ki-
ras and N-ras <96. 99, 112, 114, 115, 116> These ras oncogenes 
code for a plasma membrane bound protein, having a 
molecular weight of approximately 21,000, a highly 
related protein of 189 amino acid residues, termed p21 
protein <96> The majority of human transforming genes 
have been found to be members of the ras gene family <97• 
98
• 
99
• 
100>. These ras genes were initially found in the 
genome of certain animal sarcoma viruses <101 • 102> 
Interestingly, the ras genes have been shown to be highly 
conserved during evolution, less than 5% variation in 
amino acids have been found between p21 protein of human, 
rat, and even yeast origin <1o3, 104 > 
Ras p21 is localized at the inner side of the plasma 
membrane of the cells in both normal and activated status 
( 178, 179) Several functional groupings can be devised 
based on the products of these genes. For example: 
protein-tyosine kinase activity->the src (avian sarcoma 
virus) family; growth factor-like activity->sis (PDGF) 
family; growth factor receptor -> erb-B family; G protein 
-> Ha, Ki, and N-ras family; Nuclear protein -> myc, myb, 
fes, p53 and some other miscellanceous types; classified 
by Field and Spandidos in 1987 (105) Guanosine 
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triphosphate-binding proteins (G-proteins) are believed 
to be the mediators of intracellular transducers of 
growth regulating signals and of regulation of adenylate 
cyclase and the members of a family of guanine 
nucleotide-binding proteins including p21 gene product 
of the ras viral oncogene. 
GTPase activity and the 
G-proteins (Got, '3 , r ) have 
hydrolysis of GTP favors 
reassociation of Go(. and G pr subunits, thus inhibiting 
their interaction with the catalytic subunit of adenylate 
cyclase <106>. 
Providing the cell proliferation signal or the 
regulation of gene expression, the changes of cAMP 
quantity in different cell types could reflect the fact 
that the increased G protein binding activity of p21 
protein also affects adenylate cyclase which controls the 
level of cAMP in cells. The binding of GTP by ras p21 
protein may function as "coupling factors" in a system 
relaying signals from hormonal ligands such as adrenaline 
to the interior of the cells (signal transducing 
activity). 
More recently, it has been shown directly that ras 
proteins are indeed controlled by GTP and GDP: GTP-bound 
forms are active and GDP bound forms are inactive, by 
Trahey and McCormick <107>. 
Subsequent biochemical analysis of oncogenic ras 
mutants suggested that alteration in GTP hydrolysis or 
GDP/GTP exchange may be responsible 
transforming activity <108>. 
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for their 
GTPase Activating Protein (GAP) is a 120,000 dalton 
protein and has been purified recently and cloned from 
bovine brain and human placenta tissue by Vogel et al and 
Trahey et al <109• 110> 
activity. 
GAP can stimulate the GTPase 
It was shown, by McCormick <111 >, that failure of GAP 
to stimulate GTPase of several effector mutants is the 
result of failure to interact with p21-GTP suggesting 
that GAP is a candidate for a ras effector protein. The 
normal c-ras p21 has intrinsic GTPase activity. 
Oncogenic p21 mutants bind to GAP, but fail to undergo 
downregulation through stimulated GTPase activity. 
Because the mutants of H-ras have very weak GTPase (GTP 
hydrolysis) activity which does not allow the conversion 
of p2 l-GTP to p2 l-GDP to which it no longer binds, 
delaying termination of signal transduction. p21-GTP are 
able to interact with GAP continously and generate 
uncontrolled signal output 011 >. 
Thus, the transforming activity of an activated ras 
oncogene would involve an unopposed G protein activation 
event ( dysregulated and prolonged activity of the G 
protein as a regulatory signal) lacking the normal GTPase 
activity, because of the incapability of GAP to regulate 
the GTPase of mutated-type p21 proteins. 
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Two hot spots have been conferred on the 
transforming properties of the ras oncogenes. A single 
point mutation which substitutes a different amino acid 
for glycine (codon 12) or for glutamine (codon 61) has 
been found to be responsible for the transformed 
properties of H-ras genes in NIH 3T3 cells. The point 
mutation consists of the conversion of guanine (G) into 
thymine (T) , which results in the replacement of a 
glycine by a valine at codon position 12 of the p21 
protein encoded by the EJ cell line and T24 human bladder 
carcinoma genes <117• 118• 119>. The other one is the change 
of the base guanine (G) into adenosine (A) resulting in 
the replacement of a glycine by a glutamine at codon 
position 61 of the p21 protein encoded by the chemically 
N-nitroso-N-methylurea (NMU) - induced mammary carcinoma 
of Buf/N rats <121 >. The same kind of mutations leading 
to activation of ras oncogenes in many human tumors have 
also been reported by many investigators <for review, 202>. 
An antibody, termed Y13-259, developed by Furth et 
al <122> has been identified that is able to neutralize all 
c-ras proteins (ras p21) following microinjection into 
living cells 023>. With this antibody, it has been shown 
that ras p21 is required for the initiation of a cycle 
of DNA synthesis ( S phase) in all normal cell types 
tested <124>. When this neutralizing anti-ras antibody 
(Y13-259) was injected into NIH 3T3 cells transformed by 
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growth factor receptor - like oncogenes with tyrosine 
kinase activity, the transformed phenotype was abolished 
and cells stopped proliferating 025>. The fact that anti-
ras antibody inhibited morphologic alterations in NIH 3T3 
cells suggests that transformation - related morphologic 
alterations are associated with the result of ras 
activity. 
Pulciani and colleagues (1985) reported that 
morphologic transformation of NIH 3T3 mouse cells can 
occur upon transfection of these cells with large amounts 
(lOug) of recombinant DNA molecules carrying the normal 
human H-ras-1 proto-oncogene. Quantities of H-ras-1 RNA 
and p21 expression are highly elevated in the NIH 3T3 
transf ormants. This observation indicates that elevated 
expression of normal cellular proto-oncogenes can induce 
oncogenic transformation in cells <126>. 
Furthermore, Balmain et al (1983 and 1984) showed 
serial studies of the activation of the mouse cellular 
H-ras gene as compared with normal epidemis in chemically 
induced skin squamous cell carcinomas and benign skin 
papillomas, after sequential treatment of the Sencar mice 
with initiator DMBA and promoter TPA in the dorsal skin, 
then transfection of the NIH 3T3 cells with the DNA from 
transplantable mouse papillomas and carcinomas ' 127• 128> 
Their results also demonstrated that H-ras gene 
transcripts are elevated to a varying degree in different 
papillomas which suggests that during 
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chemical 
carcinogenesis in vivo, activation of the H-ras gene is 
a relatively early event. These studies indicate that 
the transformation-associated activation of oncogenes or 
elevation of the oncogenic products does not take place 
at the transition to malignancy, but already exists in 
most cells of the premalignant lesions. 
Bizub et al (1986) and Quintanilla et al (1986) both 
reported that the majority of DMBA-initiated papillomas 
and carcinomas posses an H-ras gene sequence with a point 
mutation at codon 61 <129• 130>. Studies of the ras protein 
p21 in tissue have been facilitated because monoclonal 
antibodies reactive with ras p21 have been utilized with 
formalin fixed, paraffin-embedded tissues and 
immunohistochemical techniques 031 • 132• 133>. 
Recently, using the monoclonal antibody aginst the 
ras p21 protein has been evaluated in a variety of human 
solid tumors by immunohistochemistry. Horan Hand and 
Thor and their colleague (1984) reported that when 
paraffin-embedded formalin-fixed tissue sections and the 
avidin-biotin complex immunoperoxidase method were used, 
the RAP monoclonal antibodies clearly defined enhanced 
ras p21 expression in the majority of human colon and 
mammary carcinomas, when compared with normal and benign 
counterparts <132>. Subsequently, they also reported that 
ras p21 expression is correlated with depth of carcinoma 
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in the bowel wall, by the same method, and is probably 
a relatively late event in colon carcinogenesis. 
Different interpretations on ras p21 expression in 
different kinds of human bladder carcinomas <134>, thyroid 
neoplasms <135>, normal and pathological liver diseases 
<136>, benign colonic conditions <13n and ovarian cancers 
(138) 
, have also been reported by immunohistochemical tests 
from human biopsy materials. 
Fujita el al (1988) also demonstrated that further 
immunohistochemical analysis of bladder tissues at 
various stages of the N-butyl-N ( 4-hydroxybutyl) 
nitrosamine (BNN) induced carcinogenic process 
indicated that the enhanced expression of p21 appeared 
early. The reactivity with RAP-5 monoclonal antibody was 
observed in diffuse hyperplastic epithelia after 5 weeks 
of exposure to BBN <139> 
(F). Epidermal Growth Factor (EGF) 
EGF, a small 53-amino-acid polypeptide, MW about 
6000 daltons, was originally isolated from mouse 
submaxillary glands by Cohen <14n and later from human 
urine <142>. 
Extracts of the submaxillary gland from the mouse, 
when injected into newborn animals, induced precocious 
eyelid opening and incisor eruption <14o, 140 , due to a 
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direct stimulation of epidermal growth and keratinization 
(143, 144) 
The biological responses elicited in the epidermis 
by EGF include increased proliferation/differentiation 
of skin tissue and accelerated keratinization in vivo, 
increased rate of macromolecular synthesis (hyaluronic 
acid, RNA, protein, DNA), enhanced prostaglandin 
synthesis, activation of glycolysis and stimulation of 
orni thine decarboxylase activity <145>. 
The effect of EGF on epidermis that is probably 
related to its mitogenic action is the enhancement of 
carcinogenesis initiated by chemicals, for example, 3-
methylcholanthrene <146• 147> Rose, et al <147> found that 
EGF could promote tumor formation by shortening the 
latent period and by increasing the average number of 
papillomas, after treatment of mouse skin with a tumor-
initiating carcinogenic chemical (3-methylcholanthrene). 
Another example was demonstiated by Reynolds et al <146> 
Meanwhile, Lee and Weinstein <148> suggested that 
these chemicals, which produce mitogenic activities 
similar to those provided by EGF, may exert their 
biological activities by interaction with EGF receptors 
(148) 
It has been shown that EGF is internalized 
subsequent to its binding to the plasma membrane receptor 
(EGF-R) and a major portion of the internalized EGF 
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ultimately is metabolized in lysosomes <145>. 
Protein kinase C which has tyrosine kinase activity 
is believed to be the major receptor site for tumor 
promoters and the cell-surface receptor for EGF. It was 
also demonstrated by Todaro et al <149> and Hollenberg et 
al <150> that some virally and chemically transformed cells 
lose their ability to bind exogenous EGF to cell surface 
receptor for optiomal growth. 
Tumor promoters bind to PKC, resulting in membrane 
association, enzyme activation, and leading to serine and 
threonine phosphorylation of the EGF-R. This event could 
result in a conformational or steric change in the EGF-
R so that the high affinity receptor is insensitive and 
can no longer bind to the EGF, and the EGF-stimulated 
tyrosine kinase is only partially activated, if at all. 
This implies an inhibitory regulation of the EGF-
stimulated tyrosine kinase. Moreover, it also inhibits 
EGF-catalyzed receptor adenyl cyclase cAMP 
autophosphorylation <151 • 152>. These actions of tumor 
promoters are apparently brought about by 
phosphorylation, through phorbol ester-mediated protein 
kinase c, of the EGF-R or a threonine residue at a key 
site on the cytoplasmic face of the receptor near the 
protein kinase C domain. PKC phosphorylates 5' 
monophosphoesterase which cleaves the phosphate 5 from 
IP3 terminating the signal. 
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Internalization of EGF occurs in a cell by means of 
a process called receptor-mediated endocytosis, which 
appears to be a common pathway for regulation of cellular 
responses to a number of polypeptides, including EGF, 
insulin, transferrin,~2-macroglobulin, immunoglobulins, 
and low-density lipoprotein (LDL) <153>-
(G). Epidermal Growth Factor-Receptor (EGF-R) 
The EGF-R is a transmembrane phosphoglycoprotein of 
170 kd with intrinsic tyrosine-specific protein kinase 
activity which autophosphorylates tyrosine residues 
rather than a serine or threonine <1 54• 155>. The receptor 
binds EGF with high affinity (KD = 10·9 to 10·10 M) and 
high specificity. 
By using 125 I-labeled m EGF, a specific receptor for 
EGF has been demonstrated in a wide variety of cultured 
cells including corneal cells, human fibroblasts, lens 
cells, human glial cells, human epidermal carcinoma 
cells, mouse fibroblast JTJ cells, granulosa cells, human 
vascular endothelial cells, human choriocarcinoma cells 
and some other cell types (Review: see 145>. 
Receptors for EGF were detected by O'keefe et al 
with crude membrane fractions prepared from a variety of 
mammalian tissues. These authors reported that placenta 
and liver membranes have a high capacity to bind EGF <156> 
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After the amino acid sequence analysis of six 
distinct peptides from human EGF receptors of A431 cells 
and placenta tissue by monoclonal immunoaffinity 
purification, Downward et al <157> were able to show that 
74 out of 83 amino acid residues are identical to those 
of the transforming protein coded by the V-erb-B oncogene 
of avian erythroblastosis virus (AEV) <15n. 
Since the receptors for EGF, TGF- oJ.. , platelet 
derived growth factor (PDGF), insulin and Insulin growth 
factor-I (IGF-I) also have associated tyrosine kinase, 
the structural relationship between the v-erb-B 
transforming protein and the EGF receptor suggests that 
other oncogenes from this subset ( src oncogenes) of 
retroviruses could be derived in part from sequences 
encoding these or other growth factor receptors, and that 
tr an sf ormation of cells by AEV may result from the 
inappropriate acquisition of a truncated EGF receptor 
molecule devoid of the extracellular control domain <157>. 
And, the viral transforming protein contained only the 
transmembrane and tyrosine kinase domain of the EGF 
receptor and lacked the extracellular domain responsible 
for EGF binding. 
As previous information in (D) Biological Aspect of 
TPA, PKC can catalyze in vitro phosphorylation of the 
EGF-R protein <159>. PKC is the receptor for tumor 
promoters <77> and when TPA is added to A431 cells, the 
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EGF-R is phosphorylated in a tryptic phosphopeptide 
identical with that phosphorylated by PKC in vitro <159• 
1~> This phosphorylation of EGF-R results in decreased 
self-phosphorylation of the receptor at tyrosine residues 
both in vitro and in vivo, and decreased EGF-stimulated 
protein (tyrosine kinase) activity in vivo <159>. Thus, 
PKC-ligand complex sets off changes in receptor affinity 
for EGF <151 • 152> and deactivates signal transduction. So, 
PKC may be activated directly by tumor promoter or 
indirectly via diacylglycerol (DG), the endogenous 
activator of PKC, derived from increased phosphatidyl 
inositol (Ptdins) turnover of IP3 stimulated by EGF and 
other hormone-receptor interactions. 
Two types of identified phosphorylation have 
different regulatory effects in EGF-R protein tyrosine 
kinase activity. Self-phosphorylation enhances activity, 
whereas, PKC-catalyzed phosphorylation depresses EGF-R 
function (IP3 + 5 monophophoesterase -> IP2 + Pi + signal 
termination, PKC phosphorylates this enzyme IP35'-
phosphomonoesterase). EGF-R activity of tyrosine 
phosphokinase has also become modulated by the receptor 
for the other peptide growth factors including platelet-
deri ved growth factor <161 >, viral oncogene encoded protein 
kinase <157• 162>, TGF-o<. <163> and PKC receptor site for tumor 
promoter phorbol ester <164>. 
It has been proven that the epidermal transformed 
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cells and squamous cell carcinomas have high levels of 
EGF-R <165• 166> All growth factors are thought to exert 
the effects in maintaining their precancerous/ 
premalignant transformed phenotypes which express the 
high level of EGF-R in transformed or altered malignant 
cells, significantly <166>. 
Recently, a tumor cell line, designated A 431 cell, 
derived from a human epidermal carcinoma of vulva, was 
found to have unique property of containing an 
exaggerated level of EGF-R on their surfaces. There are 
approximately 2 x 106 receptors per cell, a level about 
20-fold higher than the receptor levels either of normal 
or transformed cell lines <167>. 
Ozanne et al (1986) reported that A431 cells have 
a translocation and amplification of chromosome 7 that 
encodes the EGF-R <168>. The overproducition of EGF-R in 
squamous cell carcinomas must occur during neoplastic 
transformation of squamous epithelial cells. This 
increase is also found in squamous cell carcinomas biopsy 
materials which have considerably greater amount of EGF-
R than found in normal skin keratinocytes, 
adenocarcinomas, and small cell carcinomas of the lung, 
as determined by binding with the monoclonal antibody 
EGF-Rl <168>. Similar results were also demonstrated by 
some other investigators like Cowley et al <166>, Gusterson 
et al <169>, Hendler and Ozanne <170> 
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Taken together, these facts indicate that EGF-R gene 
may function as an oncogene in epidermal malignancies and 
an increased number of EGF receptors is a step in the 
progression of epidermal cells into malignancy. 
Several monoclonal antibodies reactive with EGF-R 
have been isolated for purposes of immunohistochemistry. 
Sainsbury et al (1985) reported that by using 
immunocytochemical techniques in certain breast cancers, 
there was an inverse relationship between the EGF-R and 
ER (estrogen-receptor) and a higher incidence of EGF-R 
positive tumors in the metastatic group. Additionally, 
EGF-R positive tumors were of poor differentiation and 
had characteristics associated with poor prognosis <171 • 
172) 
Another monoclonal antibody (EGF-R1) against EGF-
R, when used to evaluate lung cancers by immunoperoxidase 
technique, also showed excellent value in distinguishing 
certain kinds of positive-stained epidermoid tumors from 
negative-stained normal lung tissues <170> 
Different immunoreactivities of EGF-R in different 
human tumors such as cervical, ovarian and vulval 
carcinomas, esophageal squamous cell carcinomas, gastric 
and colonic carcinomas, sarcomas have been tested with 
the same technique by many investigators <174, 175• 176• 177> 
(H) . Transforming Growth Factor Alpha (TGF- 0() 
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Transforming growth factors (TGFs) are polypeptides 
that can induce a reversible transformation of normal 
mammalian cells in culture. Upon exposure to TGFs, 
cultured cells will undergo morphologic changes and 
acquire growth characteristics typical of malignant 
transf armed cells. These cells will also be able to form 
anchorage-independent colonies of phenotypically 
transformed cells in soft agar <180• 181>. Two different 
classes of TGFs have been identified: TGF-~ and TGF-~ 
(182) These two factors bind to different receptors and 
are unrelated at the structural level and in most 
biological activities. 
TGF- o< is present in multiple species, ranging in 
apparent size from 5-20 kd. The smallest form is 50 
amino acids long and shares about 30% structural 
similarity with the 53 residues long epidermal growth 
factor (EGF) • This sequence relationship provides a 
molecular explanation for the interaction of two growth 
factors with the same cellular receptor-- EGF-R <183>. 
Both EGF and TGF-o<. can activate a receptor-associated 
tyrosine kinase <184>. 
TGF-d... is an acidic and heat-stable transmembrane 
polypeptide, MW 6000 daltons, containing 50 amino acids, 
and can produce profound morphologic changes in rat, 
mouse and human fibroblasts. 
In 1984, Derynck et al <185> reported that, by using 
38 
mRNA derived from a human renal carcinoma cell line, they 
have identified TGF-o<. c DNA. This cDNA was found to 
encode a precusor polypeptide of 160 amino acids, from 
which TGF- d.. 50 amino acids is derived after specific 
proteolytic cleavage <185> 
amino acids <186> 
In rat, this precursor has 159 
Then, in 1987, Bringman made another finding that 
this TGF-C:Xprecursor contains an extracellular precursor 
domain of about 100 amino acids including the N-terminal 
signal sequence and the 50 amino acid TGF-0( a 
hydrophobic transmembrane domain and a 35 residue long 
cytoplasmic domain <187>. 
Examination of a variety of tumor cells by Northern 
hybridization has revealed that many carcinoma cell 
lines, {especially A431 and renal carcinoma cell lines), 
synthesize TGF- o<.. mRNA and the consistent expression of 
the TGF-o<.gene in A431 squamous cell carcinomas and renal 
carcinomas is frequently accompanied by elevated c erb 
RNA transcription and EGF-R expression {EGF-R mRNA) <188>. 
Together with the previous report made by Rosenthal et 
al {1986) that endogenous TGF-o<. expression can induce 
transformation of immortalized fibroblasts through an 
autocrine mechanism <1S9>, TGF-o( synthesis is strongly 
associated with malignant transformation. 
Since TGF-o(. has been shown to exert its action 
through the EGF-R <183• 190• 191 > it suggests that TGF-o(., 
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synthesis could act in an autocrine fashion in these 
solid tumors. 
Delarco and Todaro (1978) suggested that tumor cells 
may influence their own growth by producing TGFs which 
usurp receptors for normal growth factors and produce an 
unregulated autocrine, self-stimulating effect on tumor 
cell growth <180> 
The autocrine secretion (Sporn and Todaro) <192> of 
a growth factor in cancer cells was first described in 
mouse 3T3 cells transformed by either Moloney or Kirsten 
murine sarcoma virus (Mo-MSV and Ki-MSV respectively) <180• 
193
> These EGF-related peptides are now called typeot. 
TGFs. 
The relationship between TGF-Cl secretion and 
transformation was not clear until the results of 
experiments with temperature-sensitive mutant rodent 
sarcoma viruses were reported <193, 194• 195>. In these 
experiments, TGF- ex was not released into the medium 
unless cells were grown at a temperature permissive for 
transformation. 
Another observation made by Coffey et al (1987) was 
that TGF-ol_itself (and EGF) can induce TGF- ()!....expression 
in keratinocytes <196>. Similar autostimulation has now 
been found in certain other cases like A chain of 
platelet-derived growth factor <197>, interleukin-1 <195> 
and melanoma growth-stimulatory activity <199> 
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It has been shown that transformation induced by ras 
oncogenes lead to induction of TGF-ot. gene expression <193, 
200) Moreover, not being limited to the MuSV-transformed 
cell lines in vitro, TGF-o(. was also found in the extracts 
of chemically induced bladder carcinomas [induced in 
B6D2Fl mice by N-butyl-N-(4hydroybutyl) nitrosamine) and 
to a much lesser extent in the extracts of chemically 
induced tracheal carcinomas (which is a rat tracheal 
transplant preexposed to DMBA) <201>. 
Human solid tumors synthesize TGF- ol. and EGF-R in a 
higher level than other types of tumors. The expression 
of TGF-o( in tumor cells strongly suggests that such cells 
when in the biological status of transformation might 
indicate the presence of precancerous or premalignant 
condition. Since human skin and cultured normal human 
keratinocytes can produce TGF-cx, proved by Coffey <196>, 
the more intense TGF-o(expression was also observed in 
keratinocytes of basal cell carcinomas, squamous cell 
carcinomas, and keratinocytes in plaques from psoriatic 
patients than those from normal skin. This was reported 
by Gottlieb et al (1988), by using monoclonal antiTGF-
rX. antibodies (Al. 5) in frozen skin sections <207> 
(I). Langerhans Cells (LCs) 
Langerhans cells represent a subpopulation of 
mammalian epidermotrophic cells. 
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Epidermal Langerhans 
cells are derived from bone marrow monocytic-macrophage 
populations and bear surface receptors which implicate 
them as immunocompetent cells <264>. They have receptors 
for the Fe portion of IgG and the complement component 
C3b c2o5, 206>, and express class II MHC antigens, HLA-DR in 
human(Ia-like antigen in mouse) (207, 208, 209) . Human 
Langerhans cells also bear B-cell alloantigens (210) . 
Additional markers for Les in humans include antibody to 
the central nervous system protein s-100 (211) the 
monoclonal antibodies OKT6 (212) and NA 1/34 (213) 
Histochemically, LCs may also be identified by the 
demonstration 
triphosphatase 
of membrane associated adenosine 
(ATPase) (214, 215, 216) , and gold uptake 
staining technique <225>. 
In 1973, Silberberg identified lymphocytes in direct 
contact with Langerhans cells in sites of allergic 
contact dermatitis reactions and suggested that LCs might 
play a role in the development of delayed contact 
hypersensitivity <21 n Other investigators have shown 
that the LCs can migrate from epidermal sites to the 
adjacent draining lymph nodes and thereby help in the 
processing of the antigen <218>. It was suggested that LCs 
are concerned with the selective uptake of different 
contact allergens, stimulation of mixed lymphocyte 
reaction, and causing T cell proliferation <21n 
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The fact that antigenic agents which might be 
associated with an increased in epithelial tumors, 
including topical carcinogen DMBA application (219, 220) I 
systemic glucocorticoids <221 >, and human papilloma viruses 
c222, 223• 224 >, have been shown to result in depletion of 
epidermal Langerhans cells is further experimental 
evidence to suggest that these cells may form part of the 
immune surveillance system preventing the development of 
malignancy in squamous epithelium. Therefore, LCs may 
be involved in immunosurveillance against specific 
molecules or antigens associated with malignant 
transformation by transporting antigens to local lymph 
nodes and presenting them to specific T cells. 
Schwartz and co-workers (1981) showed that a 
decrease in density and in focal aggregates of LCs and 
loss of their complex dendritic networks were found in 
carcinogen (0.5% DMBA)-treated hamster pouch epithelium 
for 5 weeks twice-weekly, by using ATPase staining method 
(219) With the same staining procedure, Hassan et al 
(1984) reported that there was a significant increase in 
LC density after one, two or three applications of 0.5% 
DMBA, ranging from 4.5 hours to 2 weeks as compared to 
buccal pouches treated with mineral oil alone or left 
untreated <226> • 
LCs of the oral mucosa respond to early carcinogenic 
influences with an increase in number, suggestive of an 
initial cellular immune response. 
decrease of ATPase-positive 
43 
And, the significant 
LCs in long-term 
carcinogenesis experiments in which tumors continue to 
grow probably results from immunosuppression by the 
developing oral carcinomas. Other investigators have 
shown that LCs increased in number in the cancer region 
and an intimate relationship with lymphocytes in terms 
of their morphologic interaction and distribution which 
is suggestive of some immunological role and pathological 
significance <22n. Similar studies concerned with the 
distribution of LCs and staining intensities in different 
human skin tumors have also demonstrated quite different 
data <224, 22s, 229, 230> 
CHAPTER III 
MATERIALS AND METHODS 
(A) . Animals: 
Thirty-five, four to six weeks old, approximately 
100 gm, non-inbred female Golden Syrian hamsters were 
used. All animals were housed in an air-conditioned room 
with 12-hour light-dark cycle and given chow and water 
ad libitum. Two to three hamsters were kept in one cage. 
All the cages were cleaned and sterilized at least twice 
a week to maintain good hygiene and prevent spreading of 
the contaminants in this area. 
(B) . Facilities: 
All the activities of this experiment were conducted 
at HINES Veteran Administration Hospital located adjacent 
to the LUMC. The animal Room Facilities-P2 containment 
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(ARF-P2) were located on the 4th floor of the VA out-
patient-clinic, which provides for animal research and 
controls the hazard substances. Personnel involved in 
this experiment and ARF-P2 area had to follow the rules 
and regulations in order to prevent the exposure and 
contamination from the animals and biomaterials such as 
carcinogens, and radioactive substances. Researchers 
required to wear the red surgical gown over the inner 
underwears and an outer total body cover-alls which was 
removed before leaving any one of the contaminated animal 
experimental areas. Researchers also had to wear two to 
three pairs of disposable latex gloves, cover-cap, nose-
and-mouth mask (dust mist respirator) and foot-covering. 
After removing all protective clothing and barriers 
(glove, foot-covering) the individual then should wash and 
change to normal dress in the locker room. 
(C). Materials: 
1. RAP-5 anti-ras p21 monoclonal antibody was provided 
by Dr. Jeffrey Schlom, Chief of Laboratory of Tumor 
Immunology and Biology, National Cancer Institute, 
National Institutes of Health, Bethesda, MD. 
Monoclonal RAP-5 was developed, using as an 
immunogen a synthetic peptide reflecting position 
10-17 of the human Ha-ras T24 p21 (human T24 bladder 
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Ca cell line). This antibody has been shown to react 
with both the proto-oncogene p21 and point-mutated 
forms of ras p21 protein <see reference 132>, and it was 
determined to be the IgG28 isotype from mouse ascites 
fluid. 
2. Affinity-purified biotinylated horse anti-mouse 
IgG(H+L) immunoglobulin was purchased from Vector 
Laboratories Inc, Burlingame, CA. 
3. Affinity-purified polyclonal sheep antibody to an 
TGFol synthetic peptide was purchased from Triton 
Biosciences Inc, Alameda, CA. 
4. Affinity-purified biotinylated rabbit anti-sheep 
IgG (H+L) immunoglobulin was purchased from Vector 
Laboratories Inc. 
5. Monoclonal anti-epidermal growth factor 
receptor(EGF-R). This antibody is from the mouse 
ascites fluid IgG1 , isotype and it was purchased 
from Sigma Chemical Co., St Louis, MO. 
6. Rabbit IgG antiserum to s-100 protein isolated from 
cow brain was purchased from DAKO corporation, Santa 
Barbara, CA. 
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7. Normal horse serum -- Vector Laboratories Inc. 
8. 
Normal hamster serum -- Sigma Chemical co. 
Normal rabbit serum -- Jackson Immuno Research 
Laboratories Inc., West 
Grove, PA. 
Avidin-Biotin Peroxidase Complex reagents 
(Vectstatin-ABC kit) was purchased from Vector 
Laboratories Inc. 
(D). Methods: 
This experiment was begun on Jan 27, 1988, following 
two-week-adaptation period of all animals to the ARF-P2 
facility of HINES Hospital. Only those hamsters that 
appeared healthy and gained weight during the two weeks 
were used in this study. 
Application of the Chemicals 
All the applications of chemicals were done by using 
a camel hair brush No.5, after viewing the orifice and 
fundus of the pouch to cover a 2 x 2 cm2 surface area. 
A No.5 camel hair brush was dipped once in a glass bottle 
that contained the solution and wiped free of excess 
solution at each application. One assistant held the 
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hamster and the other everted the pouch by using two 
plain tissue-forceps. 
Experimental groups: 
Freshly dissolved 0.5% DMBA (approximately 670 ±.36 
ug DMBA per application, after calculating the difference 
between the weight of dry brush and wet brush for 20 
times to get the mean) in mineral oil was prepared and 
applied once to all of the left pouches of 26 hamsters 
and all aminals were left untreated for the rest of first 
week. 
Experimental control groups: 
Freshly dissolved 10 ug TPA in 0.1 ml acetone 
(approximately 3.73 ± 1.35 ug TPA per application after 
the calculating the difference between the weight of dry 
brush and wet brush for 20 times to get the mean) was 
prepared and applied to all the left and right pouches 
of 26 hamsters three times a week from the 2nd to 13th 
week. The total experimental period was thirteen weeks. 
In this investigation all the left pouches were 
experimental (DMBA/TPA) groups whereas, the right pouches 
(TPA alone) were control groups. Time for application of 
the chemicals was 6:00-9:00 A.M. every Monday, Wednesday 
and Friday. The schedule for the sacrifice of animals 
was 9:00 A.M. every Wednesday. 
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Normal control: 
Before the beginning of this experiment, one hamster 
was killed for the purpose of control tissue comparison 
and control staining. Two hamsters were selected 
randomly and sacrificed every week until the end of this 
experiment. There were another eight untreated hamsters 
which were not killed until the 20th week for the 
purposes of assessment of any later changes in pouches 
treated with DMBA/TPA. 
Sacrifice of the Animals 
Before the sacrifice, two randomly selected hamsters 
were injected with a lethal dose of sodium pentobarbital 
(5-7 ml per one hamster). Then, the everted cheek 
pouches with the exposed fundus of approximately 2 x 2 
cm2 was excised by scissors and cut into two equal 
pieces. One piece of the pouch was put into 10% formalin 
solution and the other one was put into cold normal 
saline. 
Tissue Storage and Processing 
The pouch specimens in 10% formalin solution were 
fixed six to eight hours and appropriately labelled with 
code numbers before they were put into Auto-technicon for 
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paraffin-embedding. For the formalin-fixed paraffin 
embedded tissues, 5 um serial sections (at least 15 
sections for each specimen) were cut and stained with 
hematoxylin and eosin for histologic evaluation. 
The pouch specimens in cold normal saline were 
brought immediately to the surgical Pathology Department 
(lower level of the Russo Surgical Pavillion Building of 
LUMC) and snap frozen by liquid nitrogen. Then they were 
code-labelled with numbers and stored in a deep freezer 
at a temperature between -75°c to -ss0 c. For these 
tissues, serial frozen sections of 5 um in thickness (at 
least 10-12 sections for each pouch specimen) were cut 
in a cryostat and processed for use in 
immunohistochemical staining. Those formalin-fixed, 
paraffin-embedded tissues were also sectioned (Sum) for 
immunohistochemical staining, also. 
Immunohistochemical Staining Procedure 
a). Avidin Biotin Peroxidase Complex, ABC: 
Immunoperoxidase on frozen sections 
ABC method is based on the ablili ty of the egg-
whi te glycoprotein "avidin" to bind four molecules 
of the vitamin "biotin". The avidin can attach to 
both the biotinylated secondary antibody and 
51 
biotinylated peroxidase, producing a lattice-like 
pattern with multiple peroxidase complexes. 
Finally, the peroxidase are visualized with an 
appropriate chromagen (usually, diaminobenzidine 
tetrahydrochloride). 
1. Without thawing, the frozen tissue specimens 
were placed on the cryostat chuck with OCT 
compound. The specimens were cut 3-4 micron 
thick sections and placed 2-3 sections per 
slide. Then, they were air dried for two 
hours. 
2. The slides were labelled according to the 
antibody to be used, and included the sections 
to be used for positive and negative controls, 
from some human solid tumors. 
3. Fixation: 15 minutes in 100% cold acetone for 
all slides. If the tissue was particularly 
bloody, it was washed in PBS. And, the 
fixation was extended to 20 or 25 minutes. In 
this study, cold acetone, ethanol, 2.5% 
formalin, and 2% formaldehyde were used as the 
"fixative" in all the experimental and central 
tissue sections including the normal positive 
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control of different human solid tumors to 
assure useful positive controls. These 
included colon carcinoma, breast infitrating 
ductal carcinoma, lung squamous cell carcinoma 
and small cell carcinoma, laryngeal squamous 
cell carcinoma, as well as those from the 
experimental hamster pouch sections. 
4 • Block the endogenous peroxidase of the sections 
by soaking the slides into H202/methanol 
solution (200 ml absolute methanol + 50 ml 3% 
H202) for 15 minutes at 37°C. 
5. Subsequently, 
placedin a 
(phosphate 
the slides were immediately 
coplin jar with 0.2% PBS/BSA 
buffered saline/bovine serum 
albumin). Washed two times, for each four 
minutes. Tissue sections were never permitted 
to be dried from this point until the end of 
the procedure. 
6. In a moist chamber, the sections were covered 
with a 3% solution in PBS with 0.2% BSA of 
normal serum from the species in which the link 
antibody was raised. This was done to block 
nonspecific tissue binding of subsequent 
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reagent immunoglobulins. 15 minutes at 37°c. 
Note:The dilution of BSA in PBS solution in 5 
and 6 steps could be varied from 0.2% to 1%. 
(In this study, normal horse serum blocked the 
link antibody for RAP-5 anti-p21 and anti-EGF-
R, normal rabbit serum blocked the link 
antibody for anti-TGF-~.) 
7. The slides were tapped and wiped off excess 
moisture from around the tissue sections. 
Using dispenstir, appropriate diluted primary 
monoclonal or polyclonal antibody in 0.2% 
PBS/BSA solution containing 1% normal serum 
from the link species was added to the tissue 
sections. (In this study, the dilutions were: 
1:1000 for RAP-5 anti-p21, 1:50 for anti-TGF-
o(. and 1: 200 for anti-EGF-R.) 
Incubate 15 minutes at 37°C in a moist chamber. 
However, some sections seemed to benefit from 
prolonged exposure of incubation at 4°C in the 
refregerator overnight to one to two days. 
8. The incubation of tissue sections in antibody 
solution at this and subsequent stages was 
followed by washing in three changes of PBS 
solution, 5 minutes each to remove unreacted 
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antibody. 
9. The biotinylated link antibodies against IgG 
(whole molecule) of the species from which the 
primary antibodies were prepared were diluted 
in appropriate concentration (usually 1:200 in 
PBS and applied to the sections for 30 minutes 
in room temperature or 15 minutes at 37°C). 
Note: When necessary, diluted normal hamster 
serum (1:100) was added into the link antibody 
solution to reduce the amount of the 
nonspecific background staining, where such 
unnecessary crossreactions occurred. 
10. After washing, the sections were treated with 
avid in: biotinylated horseradish peroxidase 
complex (1:200 to 1:500 in PBS) and permitted 
to react for 30 minutes at 25°C room 
temperature. 
11. Slides were washed in PBS as before, then 
rinsed with deionized water and placed in a 
peroxidase substrate solution for 3 to 5 
minutes. This solution consists of a o. 05% 
ammonium acetate-citrate buffer, pH 5.5 
containing 0.05% 3.3 1 diaminobenzidine 
b). 
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tetrahydrochloride, prepared just before use, 
filtered and 0.0075% hydrogen peroxide added. 
12. After thorough washings in distilled water, 
the sections were counterstained with 
hematoxylin, dehydrated, cleared and mounted 
in Permount. 
Avid in Biotin 
Immunoperoxidase 
embedded sections 
Peroxidase Complex, ABC: 
on formalin-fixed, paraffin-
1. Sections of formalin-fixed paraffin-embedded 
tissue were cut at 3-4 um and mounted on glass 
slides that were pretreated with 2% aqueous 
Elmer's Glue-All. 
2. After drying in a 60°C oven for 15 minutes, 
the slides were deparaff inized in two changes 
of xylene, 5 minutes for each step, then 
cleared in xylene and in two changes of 100% 
absolute alcohol, 5 minutes each. 
3 • Blockage of the endogenous peroxidase in tissue 
sections were done by soaking the sections in 
3% hydrogen peroxide/methanol solution (27 ml 
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methanol + 3 ml 30% H20 2) for 15 minutes at 37°C 
in incubator. 
4. The slides were washed well with running tap 
water, followed by deionized or distilled 
water. 
5. The following steps are quite the same with 
the method used for frozen sections starting 
from step 5. 
6. For formalin-fixed tissue sections, the slides 
were treated by the same method use for frozen 
sections beginning at step 5 (see above). 
CHAPTER IV 
RESULTS 
(A). Histologic Evaluation of Two-step DMBA/TPA Treated 
Hamster Pouch Epithelium 
Grossly, by the end of thirteen weeks, there was no 
papilloma or tumor development in the experimental and 
control groups. Only three pouches at the 12th and 13th 
weeks showed a few areas with slightly whitish color 
changes on the surf aces of the pouch mucosa. 
Histologically, these areas showed hyperkeratosis of the 
epithelium (Figure 7). 
In period I (from 1st to 5th week), DMBA/TPA and TPA 
alone groups all showed some degrees of acute 
inflammation, degeneration, necrotic changes and 
regeneration of the epithelial cells (Appendix A, iii -
table A, and iv-summary of period I ) . The toxic effect 
in the epithelium induced by DMBA was observed to be more 
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prominent than that induced by TPA. 
58 
One of the features 
caused by toxic effects of both chemicals was the cell 
dissociation pattern. Cell dissociation occurred between 
the epithelium and stroma in DMBA/TPA groups, whereas it 
occurred within the epithelium in TPA alone treated 
groups. 
The earliest atypia of the epithelium was observed 
at the 3rd week in one of the DMBA/TPA treated groups 
(Figure 2) • It showed focal compactness of surface 
keratin, dyskeratosis, basal cell proliferation, bulbous 
epithelial ridge formation and stromal reaction. This 
was interpreted as a reactive atypia due to recovery from 
the toxic effect induced by DMBA. However, by the 5th 
week, both groups showed hyperplastic changes of the 
epithelia. 
In period II (from 6th to 9th week) , prominent 
hyperchromasia of the epithelium was observed in both 
experimental DMBA/TPA and control TPA alone treated 
groups. Meanwhile, the TPA alone treated epithelium 
showed stronger effects of hyperchromasia of the 
epithelium than that of DMBA/TPA treated epithelium. 
This may be due to the lesser inflammatory reaction and 
the pleiotropic proliferative effect of promoter TPA 
(Figure 3, Appendix A, iii - table Band v). 
The most significant sequential changes in the pouch 
epithelium were observed in period III (from 10th to 13th 
week) of DMBA/TPA treated groups. 
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Focal atypia and 
minimal dysplasia were observed in six out of eight (75%) 
epithelia (Figure:4, 5, 6, a, 9 and Appendix A - vi, 
histograms and vii, summary of the results). 
However, there were only three pouches at 4th, 7th, 
12th weeks in TPA alone treated epithelium showing some 
changes of the epithelium with focal atypia or dysplasia. 
The sequential morphologic alteration in TPA alone groups 
did not parallel the features of de nova atypia/dysplasia 
as seen in the DMBA/TPA groups. Generally, DMBA/TPA 
treated groups revealed prominent hyperplastic and 
atypical changes in pouch epithelium, particularly in the 
third period (Appendix A iv, v, vi, and vii). 
In constrast to period I, atypia at this stage was 
interpreted as de nova, and was independent of initial 
cytotoxic effects by DMBA. Two of the TPA treated 
pouches at the 12th and 13th weeks showed intraepithelial 
abscess formation and regenerating epithelial cells 
without direct evidence of atypical changes in the 
epithelium. This was suggestive of the inflammatogenic 
and hyperplastogenic natures of promoter TPA (Figure 10). 
There were several pouch epithelia showing stromal 
reaction observed at the 3rd (Figure 2) and 8th weeks of 
DMBA/TPA treated groups and at the 7th, 8th, and 10th 
weeks of TPA alone treated groups. This was interpreted 
as neogeneration of cellular fibrovascular connective 
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tissue which replaced the oringinal superficial lamina 
propr ia and pushed them downward. These reactive changes 
in the stroma might result from the cytotoxic effect 
induced by both chemicals. 
A single administration of carcinogen DMBA (0.5% in 
mineral oil; approximately 670 ± 36 ug DMBA per 
application) caused morphologic changes of the epithelium 
with atypia, when promoted by TPA during the following 
12 weeks. Without the carcinogen DMBA, multiple doses 
(three times a week) of promoter TPA (10 ug in 0.1 ml 
acetone; approximately 3.73 ± 1.35 ug per application) 
did not result in morphologic changes of the epithelium 
associated with atypia during the 12 weeks. 
(B). Immunohistochemical Evaluation of ras p21,TGF-DC.,and EGF-
R in Hamster Pouch Epithelium: Effect of the Two-step 
DMBA/TPA Treatment 
i). Frozen sections of hamster pouch were used to assess 
optimal immunohistochemical staining of tissues in 
this investigation. Various fixatives and primary 
antibody dilutions were used. 
The primary antibodies were used at different 
working dilutions ranging from undiluted to 1:2000. 
The primary antibodies were used to treat control 
tissue sections in human solid tumors including 
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squamous cell carcinomas of the lung and the larynx, 
small cell carcinoma of the lung, infiltrating 
ductal carcinomas of the breast and colon carcinoma 
as well as the experimental hamster sections. 
Only the control breast carcinoma and laryngeal 
squamous cell carcinoma sections fixed either in 
100% cold acetone or 2.5% cold formalin were 
reactive with the primary antibodies. The optimal 
primary antibody working dilutions observed by 
immunohistochemical stain in cells were as follows: 
RAP-5 anti-ras p21, 1:1000; anti-TGF-0(, 1:50; anti-
EGF-R, 1:200. 
None of the tissue sections taken from the 
experimental hamster pouches were reactive with the 
primary antibodies. The cause for this is not 
known, however, this may have occurred during the 
processing of the fresh frozen sections or during 
tissue storage that resulted in the loss of any 
reacting molecules in cells of the hamster pouch 
epithelium. 
ii). Formalin-fixed, paraffin-embedded tissue sections 
of hamster pouch mucosa 
a). Monoclonal antibody RAP-5 anti-ras p21 was used 
at an optimal working dilution of 1:1000 and 
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resulted in readily observable staining of 
tissue sections. (Refer to the Appendix B -
Table I, Histograms and Figure 11 to 15 for 
the results of the stains.) Normal positive 
controls for ras p21 showed positive staining 
reactions in human breast carcinoma and oral 
squamous cell carcinoma (Figure 12, 13). Normal 
negative control (omission of the primary 
antibody) of these tumors and the experimental 
tissue sections of untreated hamster pouches 
did not show any positive reaction with the 
ras p21 antibody. 
The immunoreactivity of ras p21 was detected 
as early as the 2nd week in both DMBA/TPA and 
TPA alone treated groups. The expression of 
ras p21 protein was undetected in all normal 
tissue sections of untreated control hamster 
pouches (Figure 11) • (Note that one normal 
hamster were sacrificed preexperimentally and 
another 8 normal hamsters were sacrificed at 
the experimental 20th week.) Statistically, 
there was a significant difference between the 
DMBA/TPA and TPA alone treated groups. (Refer 
the statistical procedures to Appendix C. ) 
Additionally, there was increased staining 
intensity in cells for ras p21 observed in 
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experimental DMBA/TPA treated groups from 
period I to period III (Appendix B -Table I, 
Histograms and Figure 14, 15) • In contrast, 
this increased staining intensity of ras p21 
could not be detected in cells of hamster pouch 
epithelium in TPA alone treated groups. 
b). Polyclonal anti TGF-o<antibody was used at an 
optimal working dilution of 1:15 that resulted 
in readily observable stain in tissue sections. 
(Refer to Appendix B - Table II, Histograms and 
Figure 16 to 20 for the results of the 
staining. ) Positive controls for TGF- oC. showed 
positive staining reactions in cells of the 
oral squamous cell carcinoma and of the normal 
oral squamous cell epithelium (Figure 17,18). 
Normal negative control (omission of the 
primary antibody) in sections of those tissues 
and that of experimental tissue sections of the 
control hamster pouches did not show any 
positive reaction with the TGF-0\ antibody. 
The expression of TGF-0( protein was undetected 
in all normal tissue section of untreated 
control hamster pouches (Figure 16). 
Statistically, there was significant difference 
between the DMBA/TPA and TPA alone· treated 
groups (Appendix C). 
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The expression of the 
autocrine growth factor TGF- 0( was stained 
strongly in tissues of the DMBA/TPA treated 
hamster pouches in period II and III (Appendix 
B - Table II, Histograms and figure 19, 20) • 
Only few scattered pouch epithelium in TPA 
alone treated 
immunoreactivity 
antibody. 
groups showed 
with this anti 
positive 
TGF-c( 
c). Monoclonal antibody anti EGF-R was used at an 
optimal dilution of 1: 500 that resulted in 
readily observable stain in tissue sections. 
(Refer to Appendix B - Table III, Histograms 
and Figure 21 to 25 for the results of the 
staining.) The normal positive controls for 
EFG-R showed positive staining reactions in the 
human breast carcinoma and oral squamous cell 
carcinoma (Figure 22,23). Normal negative 
control (omission of the primary antibody) of 
the above two tumors did not show any positive 
reaction with the anti EGF-R antibody. 
The expression of EGF-R in normal hamster pouch 
epithelium was detected at the layer of spinous 
cells (Figure 21). The expression of EGF-R 
molecules was not detected at the level of 
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basal and suprabasal cell layers in normal 
pouch epithelium. However, in the case of 
reactive and proliferating conditions of the 
epithelium, the expression of EGF-R was 
detected at the level of basal and suprabasal 
cell layers {Figure 24,25). Statistically, 
there was significant difference between the 
DMBA/TPA and TPA alone treated groups (Appendix 
C). The stronger intensity of the staining was 
also observed in DMBA/TPA treated groups 
(Appendix B - Table III, Histograms and Figure 
24, 25). Only few scattered pouch epithelium 
in TPA alone treated groups showed positive 
immunoreactivity with this anti EGF-R antibody. 
(C). Immunohistochemical Evaluation of Langerhans Cells {LCs) 
in Hamster Pouch Epithelium with Two-step DMBA/TPA Effect 
Immumohistochemical staining of formalin-fixed, 
paraffin-embedded tissue sections with S-100 antibody was 
unreactive with LCs of hamster pouch epithelium in this 
investigation (Figure 27). However, normal positive 
control of several human gingival tissue sections that 
stained with s-100 antibody showed positive reaction with 
identifiable dendritic processes of Les (Figure 26). 
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Schwann cells that contain s-100 protein* in nerve fiber 
bundles of hamster pouch mucosa showed positive reaction 
(Figure 28). An additional monoclonal antibody, called 
LN-3, specific for HLA-DR(Ia-like antigen, was also used 
in this investigation. LN-3 is a murine monoclonal 
antibody (IgG28 ) reactive with HLA-DR (Ia-like) antigen 
and it was obtained from the Chemical Credential 
Immunobiologicals, Lisle, Illinois. Ia-like antigen was 
present in germinal center (lymph node and tonsil) and 
mantle zone B cells, monocytes, some interdigitating 
histiocytes and LCs in squamous epithelium. Normal 
positive control of human tonsil and human gingival 
tissue sections were tested and showed positive reaction 
with identifiable LCs (Figure 29). Like antibody to s-
100 protein, LN-3 did not react with any LCs in hamster 
pouch epithelium (Figure 30). 
(D). Statistical Analysis of the Immunoreactivity of RAP-5 
anti-ras p21, anti TGF-0(. and anti EGF-R 
The immunoreactivity of all three antibodies (RAP-
*Tissue staining with s-100 antibody: This antibody has 
been tested on several formalin-fixed, paraffin-embedded human 
tissues and shown to be strictly S-100 specific. In the 
brain, it stains glial and ependymal cells. Moreover, Schwann 
cells of the peripheral nervous system are positive. In the 
skin, melanocytes and Laugerhans cells are stained. In lymph 
nodes interdigitating reticulum cells are positive. Further, 
the antibody stains s-100 in benign and malignant melanocytic 
tumors. (Information from the company) 
r 
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5, anti TGF- o<.. , anti EGF-R) showed statistically 
significant differences between the experimental DMBA/TPA 
treated groups and control TPA alone treated groups (p 
< 0.05). Ref er the immunoreacti vi ty to Appendix B -
Table I, II, III and Histograms and refer the statistical 
procedures to Appendix C for the details. 
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Figure 1. Normal pouch mucosa showing slight hyperkeratosis 
of the epithelium with six to nine layers of 
thickness and the underlying lamina propria. (H & 
E stain, x 100) 
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Figure 2. The 3rd week pouch epithelium in DMBA/TPA groups 
showing reactive atypia of the epithelium with 
stromal reaction. (H & E stain, x 100) 
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Figure 3. The 7th week pouch epithelium in TPA alone groups 
showing very prominent hyperchromasia of the 
epithelium. (H & E stain, x 200) 
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Figure 4. The 10th week pouch epithelium in DMBA/TPA groups 
showing the disorientation and disorganizati on of 
the entire epithelial cell pattern. (H & E stain, 
x 450) 
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'igure 5. The 11th week pouch epithelium in DMBA/TPA groups 
showing few atypical epithelial cells with bi- and 
tri-lobulated nuclei in spinous cell layer. (H & E 
stain, x 450) 
73 
Figure 6. The 12th week pouch epithelium in DMBA/TPA groups 
showing hyperplastic epithelium with minimal 
dysplasia. (H & E stain, x 200) 
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Figure 7. The 12th week pouch epithelium in TPA alone groups 
showing mild hyperchromasia and hyperkeratosis of 
the epithelium. (H & E stain, x 450) 
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Figure 8. The 13th week pouch epithelium in DMBA/TPA groups 
showing prominent hyperchromasia and atypical 
changes of the epithelium. (H & E stain, x 450) 
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Figure 9. The 13th week pouch epithelium in DMBA/TPA groups 
showing prominent hyperchromasia and focal atypia 
of the epithelium. (H & E stain, x 450) 
Figure 10.The 13th week pouch epithelium in TPA alone groups 
showing intraepithelial abscess formation and 
regenerating epithelial cells. (H & E stain, x 200) 
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Figure 11.The immunostaining of RAP-5 anti-ras p21 antibody 
(1: 1000 dilution) in normal pouch epithelium showing 
completely undetected reactivity with epithelial 
cells. (ABC method, x 200) 
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Figure 12.The inununostaining of RAP-5 anti-ras p21 antibody 
in positive control of human oral squamous cell 
carcinoma showing positive reactivity with tumor 
cells. (ABC method, x 450) 
80 
• 
~ 
• 
~ 
" 
~ • , . 
• ~· , . . • • • • .# 4 • f 
' 
• •• 
Figure 13.The immunostaining of RAP-5 anti-ras p21 antibody 
in positive control of human breast carcinoma 
showing positive reactivity with tumor cells. (ABC 
method, x 200) 
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Figure 14.The immunostaining of RAP-5 anti-ras p21 antibody 
in pouch epithelium of the 7th week DMBA/TPA groups 
showing positive 
epithelial cells. 
cytoplasmic reaction 
(ABC method, x 450) 
with 
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Figure 15.The immunostaining of RAP-5 anti-ras p21 antibody 
in pouch epithelium of the 13th week DMBA/TPA groups 
showing positive 
epithelial cells. 
cytoplasmic reaction 
(ABC method, x 200) 
with 
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Figure 16. The immunostaining of anti TGF- o( antibody ( 1: 15 
dilution) in normal pouch epithelium showing 
completely undetected reactivity with epithelial 
cells. (ABC method, x 200) 
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Figure 17.The immunostaining of anti TGF-0(. antibody in 
positive control of human oral squamous epithelium 
showing positive reactivity with epithelial cells. 
{ABC method, x 200) 
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Figure 18. The immunostaining of anti TGF- o{ antibody in 
positive control of human oral squamous cell 
carcinoma showing positive reactivity with tumor 
cells. (ABC method, x 450) 
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Figure 19.The immunostaining of anti TGF-O(antibody in pouch 
epithelium of the 7th week DMBA/TPA groups showing 
positive cytoplasmic reaction with epithelial cells. 
(ABC method, x 450) 
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Figure 20.The inununostaining of anti TGF-~antibody in pouch 
epithelium of the 10th week DMBA/TPA groups showing 
positive cytoplasmic reaction with epithelial cells. 
(ABC method, x 450) 
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Figure 21.The inununostaining of anti EGF-R antibody (1:500 
dilution) in normal pouch epithelium showing strong 
cell membrane and moderately weak cytoplasmic 
reaction with epithelial cells in spinous cell 
layers. Basal and suprabasal cells show negative 
reaction. (ABC method, x 450) 
Figure 22.The immunostaining of anti 
positive control of human 
carcinoma showing positive 
cells. {ABC method, x 450) 
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EGF-R antibody in 
oral squamous cell 
reaction with tumor 
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Figure 23.The immunostaining of anti EGF-R antibody in 
positive control of human breast carcinoma showing 
positive reactivity with tumor cells. (ABC method, 
x 200) 
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Figure 24.The immunostaining of anti EGF-R antibody in pouch 
epithelium of the 9th week DMBA/TPA groups showing 
increasing positive reactivity in the cytoplasm of 
basal and suprabasal cell layers. (ABC method, x 
450) 
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Figure 25.The immunostaining of anti EGF-R antibody in pouch 
epithelium of the 12th week DMBA/TPA groups showing 
generally increasing positive reactivity in the 
cytoplasm of basal and suprabasal cell layers. (ABC 
method, x 200) 
93 
Figure 26.The immunostaining of s-100 antibody (1:300 
dilution) in positive control of human oral gingival 
epithelium showing identifiably positive reactivity 
with Langerhans cells and dendritic processes. (ABC 
method, x 450) 
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Figure 27. The immunostaining of S-100 antibody in normal 
hamster pouch epithelium showing completely 
undetected reactivity with Langerhans cells. (ABC 
method, x 450) 
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Figure 28.The inununostaining of s-100 antibody in nerve 
bundles of normal pouch lamina propria showing 
identifiably positive reactivity with nerve bundles 
of hamster mucosa. (ABC method, x 450) 
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Figure 29.The immunostaining of LN-3 antibody (1:100 dilution) 
in positive control of human oral gingival 
epithelium showing identifiably positive reactivity 
with Langerhans cells and dendritic processes. (ABC 
method, x 450) 
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Figure 30.The immunostaining of LN-3 antibody in normal 
hamster pouch epithelium showing completely 
undetected reactivity with Langerhans cells. (ABC 
method, x 200) 
CHAPTER V 
DISCUSSION 
In this investigation, a list of certain criteria in 
Appendix A ( i) were used for the evalu_ation of atypical 
features of the hamster cheek pouch epithelium based upon 
those established in previous studies that thrice-weekly 
application of 0.5% DMBA in mineral oil to the buccal pouch 
mucosa produces histologically hyperkeratotic and dysplastic 
changes of epithelium at 6 to 8 weeks, early epidermoid 
carcinoma at 8 to 10 weeks and invasive carcinomas at 10 to 
12 weeks. The microscopic and histologic changes observed 
before neoplastic development resemble the human premalignant 
conditions of oral mucosa <232>. The histological alterations 
during this period have been classified as hyperplasia without 
evidence of cellular atypia and dysplasia with a variety of 
atypical feature. 
The selection of a single application of carcinogen DMBA 
followed by multiple application of promoter TPA in this 
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investigation is based upon a scheme of initation-promotion 
phases of chemical carcinogenesis in mouse skin which has been 
studied for years. Typically, tumor initiation is caused by 
the single application of a subcarcinogenic dose of a 
carcinogen such as DMBA or urethane. Promotion is brought 
about by repeated application of a phorbol ester TPA (e.g., 
three times a week). In this model, benign papillomas begin 
their appearance at 12 to 20 weeks and by about one year 
(about 43 weeks) 40% to 60% of the animals develop squamous 
cell carcinomas (234) Different investigators have used 
different amounts of DMBA for single dose application in their 
studies. For example; Salaman and Roe: total dose 0.3mg -> 
0.15% DMBA in 0.2 ml acetone; Frei and Stephans: 1.5% DMBA in 
mineral oil; Boutwell: 75 ug DMBA in 25 ul benzene; Van Duran: 
300 ug DMBA per 100 mg acetone; Terracini et al: only higher 
doses like 100, 200, 250, 500, 1000 ug can induce tumor 
formation after a single application C235, 236, 22, 237, 25, respectively>• 
According to Scribner• s hypothesis <50> and Reddy' s and 
Fialkow' s study <49>, when the dose of DMBA is low ( o. 2 ug 
DMBA) there is very low frequency of initiated epidermal 
cells, and all tumors that develop from these cells after TPA 
promotion are promoter-dependent papillomas. A higher dose 
of DMBA initiation is responsible not only for the 
heterogeneity of promoter dependence (because of the high or 
low level of initiation), but also for the rapid development 
of the tumors in response to TPA promotion ( promoter-
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independent papillomas) <49, 50>. 
In this investigation, initiation-promotion was induced 
with a single application of the most common dose, e.g., 0.5%, 
DMBA in mineral oil (approximately 670 + 36 ug DMBA per 
applications) and followed by multiple application of TPA (10 
ug in 0.1 ml acetone equals approximately 3.73 + 1.35 ug per 
applciation) • 
As a result of this investigation, although no 
microscopic and histologic papillomas or tumors were found in 
the pouch mucosa, there were slightly whitish color changes 
observable on the surf aces of hamster cheek pouches in the 
12th and 13th weeks and they were histologically 
hyperkeratotic lesions. The sequential histomorphologic 
changes with atypia that are observed in period III (10th to 
13th week) of the DMBA/TPA treated groups, indeed supports the 
findings of others that a single application of 0.5% DMBA can 
cause variable levels of tumor initiation in epithelial cells. 
The hyperchromasia, cellular atypia and other atypical 
features that occur in the cells during initiation of tumors 
is consistent with change in nuclear DNA. This finding is 
consistent with those that report that the distortion of the 
structure of DNA over a region extending beyond the immediate 
binding site is caused by DNA adducts formation. The 
distortion of nuclear DNA occurs by syn- and anti-
stereoisomers of bay region dihydrodiol-epoxides of DMBA 
binding to DNA guanine and adenine and 06-methyl deoxyguanine 
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(06-methyl G) mutagenic lesions of DNA will generate 
predominantly 06-methyl G:T base pairs which gives G:C -> A:T 
mutations. several activating mutations including the ras 
genes have been analyzed in the mouse and rat tumors 
containing activated oncogenes induced by carcinogens. Topel 
<238> suggests that the evidence of 06-methyl G mutagenesis may 
be due to the persistence of 06-methyl G within the DNA 
sequence and the inability to fit adducts within the ONA helix 
at all positions. The cytomorphologic changes of atypia and 
dysplasia in hamster pouch epithelium is consistent with 
apparent sequential changes induced by DMBA/TPA in period I, 
II and III. 
The result of initiation is the creation of promotable 
cells which set the initiated cells apart from the rest of the 
tissue and allow the genotypically altered cells to change 
into the dormant phenotypically altered cells. Moreover, the 
following promoting action by TPA allows the expansion of 
initiated cells. The characteristics of the pleiotropic 
effects of the phorbol ester tumor promoters are that they can 
mimic the phenotypes of both normal and transformed cells. 
However, the extent of induction of phenotype of promoter TPA 
is much greater in transformed cells than in normal cells. 
It is clear that in cells which have been initiated by a 
carcinogen the effect of promoter is permanent (irreversible) 
but can not be identified until the initiated cells have 
become a major component of the cell population <53> Without 
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the initiation, most of the promoter effects are not 
permanent. After the promoter compound is removed or 
metabolized to an inactive form, the promoter-treated cells 
revert to their original phenotypes <53>. 
The TPA alone treatment-induced atypical changes of pouch 
epithelium observed at the 4th, 7th, and 12th weeks are not 
consistent with the sequential morphologic alterations of the 
epithelium with atypia (or dysplasia) of period III in 
DMBA/TPA treated groups. The observed TPA-induced 
hyperchromasia, increased mitotic figures, basal cell 
proliferation and hyperkeratosis may be attributed to the 
known pleiotropic effects of promoter TPA that result in 
nuclear macromolecular synthesis. These changes in TPA alone 
treated epithelium do not parallel de novo atypical features 
of the initiated cells induced by DMBA/TPA because of the 
inconsistency of histologic changes from period I to period 
III in this present investigation. 
The microabscess formation and reactive hyperplasia in 
epithelial cells observed at the 12th and 13th weeks of TPA 
alone treated groups (Appendix A, ii, and Figure 10) are 
suggestive of the strong inflammatogenic and hyperplasiogenic 
effects of promoter TPA. 
A strong association between enhanced inflammatory 
response and reactive hyperplasia in skin to TPA and enhanced 
sensitivity to tumor promoter by TPA has been demonstrated by 
Lewis and Adams (173) in Sencar and C57BL/6 mice. The stromal 
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reaction observed in both groups of this investigation might 
indicate the cytotoxic effect in the stroma induced by two 
chemicals. Similar stromal reactions in hamster pouch 
epithelial cultures treated with a small dose of DMBA was 
reported by Mock et al in 1983 <233>. 
This investigation demonstrates the initial histologic 
alterations induced by a single dose of DMBA and promoted by 
multiple doses of TPA in hamster buccal pouch epithelium. 
Early reactive atypia observed at the 3rd week of DMBA/TPA 
treated epithelium (Figure 2) is interpreted, following the 
recovery from acute toxic effect of carcinogen. Excluding 
reactive features, de novo expression of atypia in DMBA/TPA 
treated epithelium during the third period suggests expansion 
of the initiated cells by the action of promoter TPA. DMBA-
induced morphologic changes of enhancement of 
DNA/nucleoprotein replication (hyperchromasia) and cellular 
proliferation, 
carcinogenesis, 
particularly in the third period of 
is an important acquired property of 
carcinogen treated epithelial phenotype. This phenomenon of 
an increase in cell replication during these early steps may 
suggest "resistance" to normal mitoinhibitory effect of cell 
proliferation. Moreover, this feature confers initiation of 
the altered epithelial cells as they are readily responding 
to promoters action, in contrast, to the control counterpart. 
The expression of ras protein (p21) in DMBA/TPA treated 
epithelium, but not untreated epithelium is consistent with 
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initiation and gene activation. It has been shown that 
activation of ras gene appears to participate in the 
development of several forms of human cancer and in virally 
and chemically induced tumor <120>. 
Because of the requirement of protein product of the ras 
proto-oncogene for initiation of the S-phase (DNA synthesis) 
in NIH 3T3 cells <124> and the stimulation of G-protein binding 
activity and phosphorylation of ras oncogene protein by EGF 
<239>, the ras p21 protein can fulfill the function of a G-
protein in growth factor induced signal transduction, which 
has an integral role in the control of cell di vision and 
proliferation. • 
The sequential increased stainability of ras p21 during 
period III of DMBA/TPA treated pouch epithelium indicates its 
increased production and accumulation of this protein in 
cells. However, the earliest expression of ras p21 molecule 
can be detected at the second week of both experimental 
DMBA/TPA and control TPA alone treated groups. Previous 
studies have shown that elevated expression of the Ha-ras 
proto-oncogene is an early event in developing mouse skin 
papillomas produced by the standard two-stage carcinogenesis 
(241, 242) In Felling' s study <242>, elevated levels of Ha-ras RNA 
can be detected at the 7th week in early papillomas of Sencar 
mice and the presence of a point mutation at codon 61 can be 
detected in 9-week-old papillomas. 
In addition, elevated levels of C-rasH gene transcripts 
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in benign papillomas containing DNA with detectable 
tr an sf orming activity have also been reported by Balm in <1ZS>. 
It appears that ras genes have a very wide range of biological 
effects depending on the sequential addition of qualitative 
and quantitative changes that occur during the initiation and 
promotion phases of chemical carcinogenesis. 
While this experimental design does not provide for 
assessment of qualitative difference of ras p21, the increased 
expression of ras p21 in period III (DMBA/TPA treated groups) 
supports not only the occurrance of an effective initiation 
event but also the associated cellular atypia that is 
consistent with cell transformation. 
The scattered expression of ras p21 protein in TPA alone 
treated epithelium may be associated only with the morphologic 
changes of focal epithelial hyperplasia. The increased 
expression of ras gene has been reported in regenerating rat 
liver cells cz45>. Thus appreciation of the overexpression of 
ras p21 in neoplastic process also occurs in active stages of 
cell proliferation during normal cell regeneration. 
Finally, in the investigation, it is evident that the 
morphologic, immunohistochemical and statistical (P < 0.05) 
analyses together, provides for confirmation that the 
sequential overexpression of this molecule (ras p21 protein) 
is strongly associated with the phenotypes of the sequential 
morphologic alterations of pouch epithelium with atypia (or 
dysplasia) in DMBA/TPA treated pouch epithelium. While 
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overexpression of p21 is essential for the phenotypes of the 
initiated cells, it is not specific. 
In general, the proto-oncogene forms are thought to be 
involved in the normal growth control of cells, while the 
mutated forms appear to be responsible, in part, for the loss 
of normal growth control of neoplastic cells proliferation 
<51 > It is possible, however, that overexpression of mutated 
ras p21 occurs after a single application of DMBA and multiple 
application of promoter TPA. This might cause the observed 
early preneoplastic changes of the pouch epithelium found in 
this investigation. 
Comparison of the immunostaining in pouch epithelial 
cells of both groups with polycolonal antiTGF-0(. antibody 
supports the sequential overexpression of TGF-OC..molecule as 
it occurred only in DMBA/TPA treated groups, and not in TPA 
alone treated groups. Moreover, this significant difference 
between the experimental DMBA/TPA and TPA alone treated groups 
is supported by the statistical analysis {P < 0.05). 
Importantly, the increased immunostaining of TGF-~after 
the 6th week (in period II and III) indicated the strong 
relationship between atypia (or dysplasia) and the 
overexpressed TGF-O(in DMBA/TPA treated pouch epithelium. The 
direct evidence from previous studies have shown that TGF-« 
is frequently enhanced or induced by neoplastic transformation 
and its synthesis is very prevalent and abundant in tumor 
cells and cells transformed by oncogenes, chemicals and 
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retroviruses. This accompanied elevated TGF-O(expression in 
DMBA/TPA treated epithelium with atypia also suggests the 
implication of an autocrine or paracrine secretion. It is 
believed that transforming growth factor alpha could 
contribute to normal and neoplastic growth through autocrine 
and paracrine mechanisms <192>. The binding of TGF-0( to 
receptor (EGF-R) on the surface of the target cells initiates 
a sequence of cellular responses including the activity of the 
receptor's intrinsic tyrosine kinase, culminating in cell 
proliferation. 
The overexpression of ras p21 and TGF-~protein in this 
investigation indicates a cooperative role for these products 
in DMBA/TPA treated epithelium. It has been shown that 
mammary epithelial cells transformed by an activated ras 
proto-oncogene have increased capacity to synthesize and 
secrete their own TGF-ot <200>. Sporn and Roberts <192> stated 
that GTP-binding activity of transforming Ha-ras p21 enhanced 
by EGF, presumably by TGF- D<.. further supports that 
cooperative function of secretion of TGF-o(by ras-transformed 
cells has a role in amplifying the signalling pathway. 
In this panel of immunostaining, the expression of TGF-
ol... in normal oral oral squamous epithelium (as a normal 
positive control) is also demonstrated. TGF-o<. has been found 
to be synthesized by normal skin keratinocytes, and activated 
macrophages. The TGF-O(mRNA is also found to be transiently 
synthesized in placenta, developing kidney, the nasopharyngeal 
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pouch and the otic vesicle, indicative of its possible role 
in growth and differentiation under embryologic and 
physiologic conditions. 
Lack of the sequential responsiveness of anti TGF-Ol 
antibody in TPA alone treated epithelium is interpreted as 
being consistent with the morphologic alterations without 
atypia. Like the ras p21 protein, the increased expression 
of TGF- Cl(. is thought to be an early event in preneoplastic 
changes of the epithelium. It is also an essential, but 
nonspecific cause for the observed phenotypes of the initiated 
cells. 
It is known that normal keratinocytes of the epidermis 
express controlled amounts of the EGF-R on their surfaces. 
In this panel of immunostaining, the expression of EGF-R in 
normal pouch epithelium is detected in spinous cells. Because 
the EGF-R usually is not detected at the basal and suprabasal 
cell layers in normal pouch epithelium, this may be used as 
the criteria for any changes of the quantity of expression in 
the pouch epithelium of DMBA/TPA and TPA alone treated groups. 
From the table III (Appendix B), it is evident that the 
increased staining of cells for EGF-R in DMBA/TPA treated 
groups indicates an increased expression in these cells 
greater than those observed in the TPA alone treated groups, 
and that the difference between that two groups is 
significant. 
The increased expression of EGF-R molecule in DMBA/TPA 
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treated epithelium is based upon the positive staining 
reactions localized to the basal and suprabasal cell layers. 
This demonstrates a strong relationship between the 
consistently overexpressed EGF-R and the morphologic changes 
in DMBA/TPA treated epithelium. In this investigation, the 
increased expression of EGF-R is clearly associated with 
initiation and promotion events. 
Although the increased expression of EGF-R protein has 
been reported repeatedly in epidermal carcinoma cell lines 
such as A431 cell line and other human tumor biopsy materials 
(172-178) 
I this investigation is the first observation on the 
sequential overexpression of this receptor molecule in 
chemically-induced preneoplastic changes of hamster pouch 
epithelium. 
The EGF-R, MW 170,000, is a transmembrane glycoprotein 
formed in many cell types. Its function is to bind the 
mitogen EGF and to the transduce the signal across the cell 
membrane to cytoplasm. The EGF-R binding event induces a 
variety of receptor-mediated downregulation of growth factors, 
hormones, neurotransmitters, including ion transport, 
morphologic changes and ultimate mitogenesis. 
Protein kinase C (PKC) has been found to be the receptor 
for tumor promoters and it has an important role in 
intracellular signal transduction. A substrate for PKC is 
EGF-R itself, and activation of the former molecule appears 
to occur in response to growth factors through the generation 
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of diacylglycerol (DG) by the activation of different isotypes 
of phospholipase C (PLC) on the phosphoinositides of the cell 
membrane. The modulation of EGF-R by a pathway including DG 
and PKC provides a mechanism whereby EGF and TGF-0( can act 
sequentially in stimulating growth and cell proliferation. 
The dual overexpression of TGF-OCand EGF-R in these DMBA-
initiated, TPA-promoted sequential morphologic alterations in 
pouch epithelium further supports the role for these two 
molecules in the phenotypes of initiated cells. In addition 
to the fact that EGF-R might serve as a good indicator for 
clinical tumor behaviors and prognosis in the cases of certain 
breast and colon cancers, the increased expression of EGF-R 
in this investigation occurs in the early stages of 
preneoplastic changes of the epithelium. 
Statistically, the expression of these three molecules 
(ras p21, TGF-o<., EGF-R) shows a significant difference (p < 
0.05) between the experimental DMBA/TPA treated and TPA alone 
treated epithelium. Moreover, the phenotype-related 
morphologic alterations, particularly in the period III of 
DMBA/TPA treated groups, are strongly associated with the ras 
p21, TGF-o(.and EGF-R activities. This suggests that the gene 
activities are cooperative in the sequential overexpression 
of these molecules in experimental groups and differ from the 
lack of this sequential responsiveness to antibodies in the 
control TPA alone treated groups. The increase in expression 
of these molecules supports not only the idea of promotion in 
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which tumor promoter induces the sequential overexpression of 
phenotypes that are necessary for the initiated cells but also 
the existence of initiated cells that have been induced by 
carcinogen DMBA. 
As demonstrated (Appendix B), the im.munoreactivity of 
these three molecules are presumably due to the action of 
tumor promoter, which are, in turn, essential to the 
sequential expression of phenotypes. This event is time-
dependent, since these reactions are not significantly 
detected immediately following the DMBA application. 
The induction-maintenance of such phenotypes of DMBA-
induced initiated cells is prerequisite for preneoplastic 
changes and it may offer selective growth advantage as well 
as phenotypic changes. In addition, the sequential 
morphologic changes with atypia in the DMBA/TPA treated 
epithelium and the overexpression of these oncogenic molecules 
lend support to the thesis that carcinogenesis is a 
multigenetic-and-multistage mechanism. 
Immunologically, it is possible to induce variable 
alterations in the quantity and the quality of Langerhans 
cells in epithelium that range from acute toxic effect of DMBA 
to changes in the epithelium, although Schwartz et al and 
Hassan et al demonstrated different quantitative and 
qualitative changes in Langerhans cells of hamster pouch 
epithelium after various applications of 0.5% DMBA in mineral 
oil <219,226> 
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In this investigation, Langerhans cells of hamster pouch 
epithelium are neither reactive with s-100 nor LN-3 
antibodies. It is possible for Langerhans cells in hamsters 
to carry unique species-specific molecules that are quite 
different from that of human except for Schwann cells, as they 
contain s-100 protein and HLA-DR (Ia-like) antigen. 
CHAPTER VI 
CONCLUSION 
This investigation demonstrates the initial morphologic 
alterations induced by single dose DMBA (0.5% in mineral oil) 
promoted with sufficient intensity by TPA (10 ug in 0.1 ml 
acetone) in hamster cheek pouch epithelium. According to the 
theory of "level of initiation" proposed by Scribner, it is 
believed that single application of 0.5% DMBA must have caused 
variable levels of initiation in pouch epithelium and it might 
affect the phenotypes of initiated cells. This early event 
of the carcinogenic process in pouch epithelium is time-
dependent (12-week-promotion) and subsequent to the recovery 
due to tissue injury caused by carcinogen DMBA. Meanwhile, 
this investigatory design of initiation and promotion does not 
induce any gross tumor development by 13 weeks. 
The early reactive atypia could be induced following the 
recovery from the acute toxic effect of DMBA. Excluding 
reactive features, de novo expression of atypia in DMBA/TPA 
treated epithelia during the 3rd period (10th to 13th week) 
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suggests expansion of the initiated cells by the action of 
promoter TPA. Such atypia is not expressed in TPA alone 
treated epithelia without the initiation. Promoter TPA-
induced morphologic changes in TPA alone treated epithelia do 
not parallel the atypical features. 
The immunoreactivity of RAP-5 anti-ras p21, anti TGF-~ 
and anti EGF-R antibodies supports, in part, the phenotypes 
of initiated cells as they are responding to the promoter TPA 
and undergoing the preneoplastic changes. statistically, 
there is a significant difference (p < 0.05) between 
immunoreactivity of these antibodies found in the experimental 
DMBA/TPA and the control TPA alone treated epithelium. The 
immunohistochemical responsiveness of ras p21, TGF-tiland EGF-
R to antibodies does coincide with the morphologic changes 
with atypia in the DMBA/TPA treated epithelium, but not in the 
TPA alone treated epithelium. so, the phenotype-related, 
morphologic alterations of the epithelium are strongly 
associated with the result of ras p2 l, TGF-o<. and EGF-R 
immunoreactivities due to the sequential overexpression of 
these three molecules. As compared to the normal pouch 
epithelium, the overexpression of oncogenic molecules is an 
early event prior to the clinical benign tumor development. 
The relationship between the phenotypes of initiated cells 
and the overexpression of these three oncogenic molecules is 
interpreted as "essential" but "nonspecific". In other words, 
the activation of ras p21, TGF-~ and EGF-R molecules is a 
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basic integral event and prerequisite during the prenoplastic 
changes of the epithelium, and it coincides with the 
phenotypes of the initiated cells under the action of promoter 
TPA. 
Langerhans cells in hamster pouch epithelium may carry 
unique molecules quite different from those in humans species 
except for Schwann cells, due to the immunohistochemical 
unresponsiveness to S-100 and LN-3 antibodies. 
The sequential morphologic changes with atypia in single 
dose DMBA-initiated and multiple doses TPA-promoted pouch 
epithelium and increased expression of ras p21 oncogene 
product, transforming growth factor alpha and epidermal growth 
factor receptor suggest the emergence and diversity of the 
initiated cells following the sequential evolution of 
carcinogenic process that is a multistage-and-multi genetic 
mechanism. 
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APPENDIX A 
(i) 
criteria for Histologic Evaluation of Hamster Pouch Epithelium 
(1). Epithelial hyperplasia: proliferation of epithelium 
including acanthosis, basal cell proliferation or 
elongation of epithelial ridges. 
(2). Focal atypia: changes in individual cells without 
disorientation or disorganization of their arrangement 
and pattern. 
a). compactness of surface keratin 
b). dyskeratosis 
c). keratin pearl formation in the spinous cell layer 
d). hyperchromasia 
e). large prominent nucleoli 
f). cellularpleomorphism: anisocytosis, poikilocytosis 
g) • alteration of N/C ratio 
h). loss of the cellular polarity 
i). increase in the number of mitoses 
j). suprabasal mitosis 
k). atypical or bizzare mitosis 
1). bulbous epithelial ridges 
m). lack of the cohesiveness of the epithelial cells 
(3). Dysplasia: atypia 
disorganization or 
arrangement. 
as the above criteria with 
disorientation of the cellular 
minimal - less than 4 items 
moderate - at least 5 items 
severe - at least 8 items 
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APPENDIX A 
(ii) 
Brief Histologic Report and Staging of Each Pouch Epithelium 
*Brief Histologic Findings from 1st week to 13th week: 
1). 1-27-N (Normal Hamster Pouch) (Figure 1) 
Normal Hamster Pouch is composed of a keratinized 
stratified squamous epithelium and its underlying lamina 
propria of fibrous connective tissue. 
A). stratum corneum (parakeratosis or orthokeratosis): 
usually one to two layers of thickness 
B). stratum granulosum (granular cell layer): with 
keratohyaline granules (one layer of thickness) 
C). stratum spinosum (spinous cell layer): from 
suprabasal polyhederal cells to upper spinous cells 
with intercellular spaces between cells (three to 
five layers of thickness) 
D). stratum basale (basal layer): low cuboidal to tall 
columnar cells (one layer of thickness) 
E). lamina propria: 
a). superficial layer - dense fibrocollagenous 
connective tissue containing moderate amount 
of fibroblasts, small blood vessels and nerve 
bundles. There is no papilla in superficial 
lamina propria, epithelial rete-ridges and 
salivary glandular structures. 
b). deep layer (submucosal layer) - It is a loose 
fibrous conncetive tissue with blood vessels 
and nerves of larger sizes and muscle bundles. 
2). 2-3-1W,D-A-L't 
separation of the epithelium from the stroma 
epithelial necrosis 
intensive acute inflammation 
scattered dyskeratotic cells 
colloid bodies formation 
140 
atypical giant nucleated cells in the spinous cell 
layer (due to toxic effect) 
mild acanthosis 
minimal hyperchromasia of basal and suprabasal cells 
with prominent nucleoli 
roughness of the basement membrane 
3). 2-3-1W,D-B-L't 
severe inflammation 
focal mononuclear cell infiltration in the 
epithelium 
hyperkeratosis 
colloid bodies formation 
dyskeratotic cells (dyskeratosis) 
few giant nucleated cells with prominent nucleoli 
in the suprabasal & spinous cell layer 
very mild cell dissociation in the epithelium 
mild basal cell proliferation and hyperchromasia 
mild disorientation of the cell pattern, focally 
epithelial hyperplasia 
intraepithelial microabscess formation 
4). P-2W,DT-A-L't 
focal hyperkeratosis 
focal acanthosis 
moderate inflammation in the stroma (lymphocytes, 
monocytes, neutrophils, few mast cells) 
focal basal cell proliferation 
granulation tissue formation 
few dyskeratotic cells 
5). P-2W, T-A-R't 
focal acanthosis 
focal basal cell proliferation 
focal compactness of surface keratin 
mild hyperchromasia of the basal cells 
mild mononuclear cell infiltration 
6). P-2W,DT-B-L't 
focal acanthosis 
mononuclear cell infiltration with microabscess 
formation 
lymphocytes, monocytes predominant 
7). P-2W,T-B-R't 
141 
focal compactness of surface keratin (or compact 
hyperkeratosis) 
few inflammatory cells (lymphocytes) 
epithelial dissociation from the stroma, partially 
focal acanthosis 
mild hyperchromasia of the basal cells 
few dyskeratotic cells 
8). P-3W,DT-A-L't 
focal compactness of surface keratin 
increased mitotic figures 
mild hyperchromasia of basal cell layer 
basal cell proliferation 
few suprabasal mitoses 
few scattered dyskeratotic cells 
lymphocytes & mononuclear cell infiltration 
9). P-3W,T-A-R't 
compact keratin formation 
focal acanthosis 
basal cell proliferation and focal mild 
hyperchromasia 
few inflammatory cells 
subcorneal microabscess formation (neutrophils) 
10). P-3W,DT-B-L't 
focal compact hyperkeratosis 
acanthosis 
severe inflammation with lymphocytes, monocytes, 
mast cells 
neogeneration of cellular f ibrovascular tissue 
beneath the epithelium 
disorientation of the basal/suprabasal cells 
basal cell proliferation with minimal dysplasia and 
bulbous ridge formation (no invasion) 
severe mononuclear cell infiltration 
colloid bodies formation 
dyskeratosis 
increased mitotic figures 
slight separation between epithelium & stroma 
minimal dysplasia of the epithelium 
reactive atypia of the epithelium (due to the toxic 
effect of DMBA) 
11). P-3W,T-B-R't 
few cells show granular and clumped chromatin in the 
nucleus 
suprabasal mitosis 
few inflammatary cells (neutrophils) 
focal acanthosis with basal cell proliferation 
12). P-4W,DT-A-L't 
intraepithelial microabscess formation 
moderate inflammation in the stroma 
suprabasal mitosis 
epithelium dissociation 
dyskeratotic cells 
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few giant nucleated cells with prominent nucleoli 
in the spinous cell layer 
focal acanthosis with basal cell proliferation 
few cells with pleomorphic, hyperchromatic nuclei 
in the basal cell layer 
13). P-4W,T-A-R't 
subcorneal microabscess formation 
focal acanthosis with basal cell proliferation and 
mild hyperchromasia 
increased mitotic figures 
suprabasal mitosis 
slight disorientation of cell pattern in the 
epithelium 
mononuclear cell infiltration 
moderate inflammation in the stroma 
focal atypia of the epithelium 
14). P-4W,DT-B-L 1 t 
focal acanthosis and hyperkeratosis 
moderate inflammation 
microabscess formation in the subcorneal cell layer 
mild mononuclear cell infiltration 
15). P-4W,DT-B-R 1 t 
focal compactness of surf ace keratin 
focal acanthosis and basal cell proliferation 
subcorneal microabscess formation 
few colloid bodies formation 
dyskeratotic cells 
few inflammation cells 
mild mononuclear cell infiltration 
16). P-5W,DT-A-L't 
few inflammatory cells 
mild separation between the epithelium and stroma 
mild compact hyperkeratosis 
143 
17). P-SW,T-A-R't 
focal acanthosis 
focal microabscess formation 
few basal cells show the 
chromatin 
in the epithelium 
granular or clumped 
few inflammatory cells 
18). P-SW,DT-B-L't 
subcorneal microabscess formation 
focal compactness of surf ace keratin 
dyskeratotic cells 
mild inflammation 
separation between the epithelium and stroma 
few suprabasal mitoses 
19). P-5W,T-B-R 1 t 
mild elongation of epithelial ridges 
mild acanthosis 
mild hyperkeratosis 
mild inflammation (lymphocytes, monocytes) 
granulation tissue formation 
20). P-6W,DT-A-L't 
subcorneal and intraepithelial microabscess 
formation 
suprabasal mitosis 
colloid bodies formation 
epithelium necrosis 
cell dissociation in basal cell layer, focally 
moderate inflammation 
mononuclear cell infiltration 
focal area showing the giant nucleated cells with 
prominent nucleoli in the spinous cell layer 
focal atypia of the epithelium 
21). P-6W,DT-A-R't 
hyperkeratosis 
minimal inflammation 
focal acanthosis 
22). P-6W,DT-B-L't 
some inflammatory cells 
no significant changes in the epithelium 
23). P-6W,T-B-R 1 t 
focal acanthosis and basal cell proliferation 
some inflammatory cells 
no singificant changes in the epithelium 
24). P-7W,DT-A-L't 
mild inflammation in the stroma 
focal acanthosis and mild hyperkeratosis 
mild hyperchromasia in basal cell layer 
focal compact hyperkeratosis 
focal basal cell proliferation 
25). P-7W,T-A-R't 
focal hyperkeratosis 
moderate hyperplasia of the epithelium 
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moderate hyperchromasia of the basal cells with some 
squamoid differentiation 
mild cell dissociation in basal cell layer 
neogeneration of cellular f ibrovascular tissue with 
roughness of the basement membrane 
moderate inflammation 
few colloid bodies formation 
some dyskeratotic cells 
granulation tissue formation in the stroma 
intraepithelial microabscess formation 
epithelium necrosis 
mild dissociation of the epithelium from the stroma 
elongation of epithelial ridges with dyplasia 
disorientation of the suprabasal and basal cell 
layers 
no invasion of the dysplastic epithelium 
minimal dysplasia of the epithelium 
26). P-7W,DT-B-L 1 t 
focal compactness of surf ace keratin 
some inflammatory cells ( neutrophils, mast cells} 
27). P-7W,T-B-R't 
mild acanthosis of epithelium 
few inflammatory cells 
28). P-8W,DT-A-L 1 t 
hyperkeratosis with compactness of surface keratin 
mononuclear cells infiltration 
mild neogeneration of cellular f ibrovascular tissue 
lymphocytes, monocytes, and neutrophils 
focal basal cell proliferation with mild 
hyperchromasia 
focal epithelial hyperplasia 
29). P-SW,T-A-R't 
focal compactness of surf ace keratin 
focal acanthosis of the epithelium 
few inflammatory cells 
30). P-SW,DT-B-L't 
mild inflammation 
focal compactness of surf ace keratin 
no significant changes in the epithelium 
31). P-SW,T-B-R't 
mild compactness of surf ace keratin 
few inflammatory cells 
mild acanthosis 
slight hyperchromasia in basal cell layer 
32). P-9W,DT-A-L't 
very few inflammatory cells 
focal acanthosis 
mild hyperchromasia in the basal cell layer 
a lot of perivascular mast cells infiltration 
mild basal cell proliferation 
33). P-9W,T-A-R 1 t 
few inflammatory cells 
edematous change in the stroma 
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focal acanthosis with mild basal cell proliferation 
34). P-9W,DT-B-L 1 t 
mild inflammation (lymphocytes, neutrophils, and 
mast cells) 
focal basal cell proliferation 
focal acanthosis 
scattered dyskeratotic cells with pyknotic nuclei 
focal hyperkeratosis 
35). P-9W,T-B-R't 
mild neogeneration of cellular f ibrovascular tissue 
intensive mononuclear cell infiltration 
mild hyperkeratosis 
focal acanthosis and mild basal cell proliferation 
focal hyperchromasia of basal cells 
lymphocytes, monocytes, mast cells in the stroma 
36). P-lOW,DT-A-L't 
subcorneal microabscess fromation 
dyskeratotic cells 
suprabasal mitosis 
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cell dissociation in the basal cell and suprabasal 
cell layer 
mononuclear cell infiltration 
focal acanthosis 
few giant nucleated cells in upper spinous cell 
layer 
focal basal cell proliferation 
colloid bodies formation 
granulation tissue formation in the stroma 
moderate inflammation 
mild disorientation of the suprabasal and spinous 
cell layers 
focal atypia of the epithelium 
37). P-lOW,T-A-R't 
small amount of neogeneration of cellular 
f ibrovascular tissue 
cytoid bodies formation and few dyskeratotic cells 
mild inflammation 
focal acanthosis 
38). P-lOW,DT-B-L't 
scattered dyskeratotic cells 
few inflammatory cells 
focal acanthosis 
39). P-lOW,T-B-R't 
mild inflammation 
focal acanthosis 
no significant changes in the epithelium 
40). P-llW,DT-A-L't 
focal hyperkeratosis 
focal acanthosis 
moderate hyperchromasia of basal cell layer 
few cells with bi/tri-lobulated nuclei in the 
suprabasal and spinous cell layer 
cell dissociation in the basal cell layer 
mild inflammation (lymphocytes, monocytes, mast 
cells) 
mild mononuclear cell infiltration 
mild squamoid differentiation in basal cell layer 
perivascular mast cells infiltration 
few cells with hyperchromatic and pleomorphic nuclei 
in the basal cell layer 
focal atypia of the epithelium 
41). P-llW,T-A-R't 
slight inflammation & edema in the stroma 
no significant changes in the epithelium 
42). P-llW,T-B-L't 
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mild cell dissociation in the basal cell layer 
moderate inflammation (lymphocytes, neotrophils, 
mast cells) 
focal acanthosis 
basal cell proliferation with hyperchromasia 
mononuclear cell infiltration 
intraepithelial/subcorneal layer microabscess 
formation 
few degenerating epithelial cells with pyknotic 
nuclei 
43). P-llW,T-B-R't 
focal acanthosis 
mild inflammation 
large amount of mast cells in the strma 
focal bascal cell proliferation 
mild mononuclear cell infiltration 
moderate inflammation 
44). P-12W,DT-A-L't 
focal hyperkeratosis of the epithelium 
moderate inf lamination 
focal basal cell proliferation 
intraepithelial microabscess formation 
focal acanthosis 
generalized hyperchromasia of basal cells with some 
pleomorphic nuclei and mild squamoid differentiation 
intensive mononuclear cell infiltration 
some atypical cells with clear cytoplasm and 
pleomorphic nuclei in basal cell layer 
cell dissociation between the basal cell layer and 
stroma 
focal disorientation/disorganization of the cell 
pattern 
minimal dysplasia of the epithelium 
45). P-12W,T-A-R't 
focal acanthosis 
few inflammatory cells 
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scattered dyskeratotic cells 
mild hyperchromasia in basal cell layer 
46). P-12W,DT-B-L't 
focal acanthosis 
mild basal cell proliferation with focal 
hyperchromasia 
mild inflammation 
epithelial necrosis 
some squamoid differentiation in the basal cell 
layer 
mild pleomorphism of the basal cell layer 
focal disorientation of cell pattern 
minimal dyplasia of the epithelium 
47). P-12W,T-B-R 1 t 
focal hyperkeratosis (compact type) 
cell dissociation in the basal cell layer 
epithelial necrosis 
basal cell hyperchromasia 
moderate inflammation 
focal acanthosis 
elongation of epithelial ridges with 
hyperchromatic epithelial cells 
focal basal cell proliferation 
mild disorientation of the cell pattern 
minimal dysplasia of the epithelium 
48). P-13W,DT-A-L't 
focal hyperkeratosis of the epithelium 
few colloid bodies formation 
few dyskeratotic cells 
some 
atypical giant nucleated cells in the upper spinous 
cell layer 
generalized hyperchromasia of the basal cells with 
mild pleomorphism 
focal basal cell proliferation with squamoid 
differentiation 
focal cell dissociation in the basal cell layer 
moderate inflammation 
loss of cell pattern and arrangement, focally 
mononuclear cell infiltration, intensively 
minimal dysplasia of the epithelium 
49). P-13W,T-A-R't 
few inflammatory cells 
focal acanthosis 
no significant changes in the epithelium 
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50). P-13W,DT-B-L't 
focal acanthosis 
basal cell proliferation with moderate 
hyperchromasia 
moderate inflammation (lymphocytes, mast cells, 
neutrophils) 
some squamoid differentiation in the basal cell 
layer 
few dyskeratotic cells 
granulation tissue formation 
minimal dysplasia of the epithelium 
51). P-13W-,T-B-R 1 t 
focal acanthosis 
focal basal cell proliferation 
severe intraepithelial abscess formation (lym-
phocytes, neutrophils) 
severe inflammation in the stroma 
focal regenerating epithelial cells between the 
areas of abscess formation 
52). P-20W,C-A 
53). P-20W,C-B 
54). P-20W,C-C 
55). P-20W,C-D 
56). P-20W,C-E 
57). P-20W,C-F 
58). P-20W,C-G 
59). P-20W,C-H 
*All the control groups showed the 
normal histology of hamster pouch 
epithelium. 
APPENDIX A 
(ii) 
*Brief Staging of Each Pouch Epithelium 
Acute inf ammation ==> AI 
Pustule/Abscess ==> P/A 
Epithelial necrosis/degeneration ==> En/d 
Chronic inflammation ==> CI 
Epithelial hyperplasia ==> EH 
*Focal atypia ==> FA 
minimal ==> Dmi 
*Dysplasia moderate ==> Dmo 
severe ==> Dse 
*Stromal reaction 
(Neogeneration of f ibrovascular tissue) ==> SR 
* * * * * Al P/A Enid Cl EH FA Dmi Dmo Dse SR 
1). 1 ·27-N nonnal pouch 
2). 2·3·1W,D·A·L 1 t x x 
3). 2·3-1W,D·B·L't x x x x x 
4). P-2W,DT-A-L't x x 
5). P·2W,T-A-R 1 t x 
6). P-2W,DT·B·L 1 t x x 
7). P·2W,T-B·R 1 t x 
8). P-3W,DT·A·L't x x 
9). P·3W,T-A·R't x x 
10). P·3W,DT·B·L't x x x x x 
11). P·3W,T-B·R 1t x x 
12). P·4W,DT·A·L't x x x x 
13). P-4W,T-A-R 1t x x x x x 
14). P·4W,DT-B·L't x x x 
150 
151 
* * * * * Al P/A En/d CI EH FA Dmi Dmo Dse SR 
15). P·4W,T-8·R't x x x 
16). P·5W,DT·A·L 1 t x 
17). P-5W,T·A·R•t x x 
18). P-5W,DT·8-L 1t x x 
19). P·5W,T·8·R't x x 
20). P·6W,DT-A·L 1 t x x x x x 
21). P-6W,T·A-R't x x 
22). P-6W,DT·8-L 1t x 
23). P·6W,T·8·R't x 
24). P-711,DT-A·L't x x 
25). P-711,T·A-R't x x x x 
26). P·711,DT·8-L 1 t x 
27). P-711,T-8-R't x x 
28). P-8W,DT-A-L't x x x x 
29). P·8W,T·A·R 1 t x 
30). P-8W,DT·8-L 1 t x 
31). P·8W,T-8·R't x x 
32). P·9W,DT-A·L 1 t x x x x 
33). P-9W,T·A-R't x x x 
34). P-9W,DT-8·L 1 t x x 
35). P·9W,T-8·R 1 t x x x 
36). P·10W,DT-A-L't x x x 
37). P·10W,T-A·R't x x x 
38). P-10W,DT-8·L't x x x 
39). P-10W,T·8·R't x 
40). P·11W,DT·A·L 1t x x x 
41). P·11W,T·A·R't x 
42). P·11W,DT-8·L't x x x 
43). P·11W,T·8·R 1t x x x 
44). P·12W,DT·A·L 1t x x x x 
45). P·12W,T·A·R't x x 
* * * * * 
Al P/A En/d Cl EH FA Dmi DlllO Dse SR 
46). P·12W,DT·B·l 1 t x x x x x 
x x x x x 
48). P·13W,DT·A·l 1 t x x x 
49). P·13W,T·A·R 1 t x x 
50). P·13W,DT·B·l't x x x 
51). P·13W,T·B·R 1 t x x x x x 
52). P·20W,C·A control group ········> normal pouch 
53). P·20W,C·B control group ······-·> nor111&l pouch 
54). P·20W,C·C control group ·······-> normal pouch 
55). P·20W,C·D control group ········> normal pouch 
56). P·20W,C·E control group ---·····> normal pouch 
57). P·20W,C·F control group ········> normal pouch 
control group --------> normal pouch 
59). P·20W,C·H control group ····--··> normal pouch 
* summary: 
A. Number of epithelial dysplasia/atypia ==> 11 pouches 
Left side (DMBA + TPA) ==> 8 pouches 
Right side (TPA) ==> 3 pouches 
B. The earliest changes of dysplasia/atypia 
DMBA/TPA treated ==> 3rd week 
(others: 6th,10th,llth,12th,13th) 
TPA treated only ==> 4th week 
(others: 7th,12th) 
c. Number of stromal reaction ==> 5 pouches 
Left side (DMBA + TPA) ==> 2 pouches 
Right side (TPA) ==> 3 pouches 
D. The earliest changes of stromal reaction 
DMBA + TPA treated ==> 3rd week 
TPA treated only ==> 7th week 
(the others: 8th, 9th, 10th) 
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APPENDIX A 
(iii) 
Comparison of the DMBA & TPA Effect 
During the Carcinogenesis Process 
TABLE A: 1st - 5th week (Period I) 
I nfl anmat ion 
- acute & chronic 
- epithelial dissociation 
- epithelial necrosis 
- intraepithelial abscess formation 
- mononuclear cell exocytosis 
- perivascular mast cell infiltration 
Epithelial Changes 
c~ct keratinization 
hyperkeratosis 
acanthosis 
colloid bodies 
basal cell hyperplasia/proliferation 
bulbous epithelial ridge formation 
acantholysis of the epithelial cells 
Atypia/Dysplasia 
- large prominent nucleoli 
- hyperchromasia 
- pleanorphism 
- increased mitosis 
• si..,rabasal mitosis 
- atypical mitosis 
- loss of cellular orientation/arrangement 
• lack of epithelial cells cohesiveness 
- dyskeratosis 
• squamoid appearance in basal cell layer 
+++ 
+ 
++ 
++ 
++ 
+ 
+ 
+/-
++ 
+ 
+ 
+ 
+/-
+ 
+/-
+/· 
+/-
+/-
+/· 
+/-
+ 
Stromal Reaction +/-
(neogeneration of f ibrovascular connective tissue) 
Note: +++ strong reaction 
++ moderate reaction 
+ weak reaction 
+/· occasionally weak reaction 
negative reaction 
++ 
+/· 
+ 
+ 
+ 
+/-
+ 
++ 
+/-
+ 
+/-
+/· 
+/-
+/· 
+/· 
+/-
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APPENDIX A 
(iii) 
Comparison of the DMBA & TPA Effect 
During the Carcinogenesis Process 
TABLE B: 6th • 9th week (Period JI) 
I n I nfl arrmati on 
• acute & chronic 
• epithelial dissociation 
· epithelial necrosis 
- intraepithelial abscess formation 
· lllOl'lOnUClear cell exocytosis 
• perivascular mast cell infiltration 
Epithelial Changes 
• COR-.:>SCt keratinization 
- hyperkeratosis 
• acanthosis 
• colloid bodies 
- basal cell hyperplasia/proliferation 
- bulbous epithelial ridge formation 
- acantholysis of the epithelial cell 
Atypia/Dysplasia 
· large prominent nucleoli 
· hyperchromasia 
- pleomorphism 
- increased mitosis 
• suprabasal mitosis 
- atypical mitosis 
· loss of cellular orientation/arrangement 
• lack of epithelial cells cohesiveness 
· dyskeratosis 
• squamoid appearance in basal cell layer 
Stromal Reaction 
(neogeneration of fibrovascular cornective tissue> 
Note: +++ strong reaction 
++ moderate reaction 
+ weak reaction 
+/· occasionally weak reaction 
negative reaction 
++ 
+ 
+ 
++ 
+ 
++ 
++ 
+ 
+ 
+ 
+ 
+/-
+/· 
+/· 
+ 
+/· 
+/-
+/· 
+/-
+/-
+/· 
++ 
+ 
+ 
+ 
+/· 
++ 
++ 
+ 
+ 
+/· 
+ 
+/· 
+/· 
++ 
+/· 
+/-
+/-
+/· 
+/-
+ 
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APPENDIX A 
(iii) 
Comparison of the DMBA & TPA Effect 
During the Carcinogenesis Process 
TABLE C: 10th - 13th week (Period Ill) 
lnflanmation 
- acute & chronic 
- epithelial dissociation 
- epithelial necrosis 
• intraepithelial abscess formation 
• lllOl'\Ol"IUC l ear cell exocytos is 
• perivascular mast cell infiltration 
Epithelial Changes 
- conpact keratinization 
- hyperkeratosis 
- acanthosis 
- colloid bodies 
- basal cell hyperplasia/proliferation 
- bulbous epithel fal ridge formation 
• acantholysis of the epithelial cells 
Atypia/Qysplasia 
- Large prominent rucleoli 
- hyperchromasia 
• pleomorphism 
- increased mitosis 
- suprabasal mitosis 
- atypical mitosis 
- loss of cellular orientation/arrangement 
- lack of epithelial cells cohesiveness 
- dyskeratosis 
- squamofd appearance in basal cell Layer 
Stromal Reaction 
(neogeneration of fibrovascular connective tissue) 
Note: +++ strong reaction 
++ lllOderate reaction 
+ weak reaction 
+/· occasionally weak reaction 
negative reaction 
++ 
++ 
+ 
+ 
+++ 
++ 
+/-
++ 
+ 
+ 
++ 
+/-
+ 
+ 
++ 
+ 
+ 
+ 
++ 
+ 
++ 
++ 
++ 
+ 
+ 
+ 
+ 
++ 
+/-
++ 
+ 
+ 
+ 
+/-
+/-
+++ 
+/-
+/-
+/-
+/-
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APPENDIX A 
(iv) 
Summary of Period I: 
Similarity: 
1. DMBA and TPA can cause some degrees of inflammation, 
degeneration, necrosis and regeneration of epithelial 
cells. 
2. By 5th week, DMBA and TPA all caused some hyperplastic 
effect on epithelium. 
3. Few scattered atypical cells can be found in DMBA/TPA and 
TPA alone groups at the 3rd & 4th weeks, respectively. 
Difference: 
1. DMBA can cause more severe inflammmatory (toxic) effect 
in host response. (more abscess formation) 
2. DMBA -- Dissociation occured between the epithelium and 
stroma. 
TPA -- Subcorneal cell layer separation. 
3. More bulbous type of epithelial proliferation in DMBA/TPA 
groups. 
4. DMBA/TPA groups caused a very early reactive atypia due 
to the recovery form acute toxic effect of DMBA in the 
epithelium at the 3rd week. 
5. At the 4th week, TPA alone treated pouch showed the 
earliest focal atypia of the epithelium. (due to 
increased suprabasal mitosis, slight disorientation of 
cellular pattern and basal cell proliferation) 
6. The earliest stromal reaction occurred in DMBA/TPA groups 
(the 3rd week). 
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APPENDIX A 
(iv) 
Summary of Period II: 
Similarity: 
1. Both DMBA/TPA and TPA groups had about the same degree 
of inflammation and epithelial changes. 
2. TPA caused the stromal reaction, too. 
Difference: 
1. TPA alone groups did show a little stronger effect to 
cause the hyperchromatism, epithelial hyperplasia and 
squamoid appearance of the epithelium, which might be 
associated with the pleiotropic influence of TPA in vivo. 
2. TPA caused a minimal dysplasia of epithelium at 7th week. 
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APPENDIX A 
(iv) 
Summary of Period III: 
Similarity: 
1. Both DMBA/TPA and TPA alone groups had about the same 
degree of inflammatory reaction. 
Difference: 
1. DMBA/TPA groups had more pronounced hyperplastic 
proliferation and more atypical changes in the 
epithelium. (de novo changes of dysplasia/atypia) 
2. Although TPA caused a very prominent hyperchromasia in 
the epithelium. (increased the number of dark 
keratinocytes), the morphologic changes in TPA alone 
groups were not consistent with the atypia/dysplasia. 
3. TPA caused more stromal reaction. 
Period 
Period II 
Period III 
APPENDIX A 
(v) 
Comparison of I, II & Ill period CDMBA/TPA gr0l4)6) 
lnfl81T1118tion 
+++ 
++ 
++ 
Epithelial Hyperplasia 
+ 
+ 
++ 
Atypia/Dysplasia 
+/-
+/-
++ 
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=================================================================================================== 
Period 
Period II 
Period Ill 
Comparison of I, II & I II period (TPA gr0l4)6) 
I nfl 81T1118t ion 
+ 
+ 
++ 
Epithelial Hyperplasia 
+ 
++ 
++ 
Atypia/Dysplasia 
+/-
+/-
+/-
Time 
(week> 
13th 
12th 
11th 
10th 
9th 
8th 
7th 
6th 
5th 
4th 
3rd 
2nd 
1st 
APPENDIX A 
(vi) 
Histogram of the Results of Histologic Evaluation 
Inf: lnfl8111118tion 
EH: Epithelial Hyperplasia 
FA: Focal Atypia 
Dmi: Minimal Dysplasia 
Omo: Moderate Dysplasia 
Dse: Severe Dysplasia 
c:::J B h81118ter pouch 
1111 A hamster pouch 
'---1--1---1--1--1--1-----
lnf EH FA Dmi Omo Dse Epithelial 
Changes 
* DMBA + TPA treated pouches (left pouch) 
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Time 
(week) 
13th 
12th 
11th 
10th 
9th 
8th 
7th 
6th 
5th 
4th 
3rd 
2nd 
1st 
APPENDIX A 
(vi) 
Histogram of the Results of Histologic Evaluation 
11111111111111111 
111111111 
Inf: Inflanmation 
EH: Epithelial Hyperplasia 
FA: Focal Atypia 
Dmi: Minimal Dysplasia 
Dmo: Moderate Dysplasia 
Dse: Severe Dysplasia 
c:::::::J B hamster pouch 
1111 A hamster pouch 
:--:---:---:--:--1-----
Inf EH FA Dmi Dmo Dse Epithelial 
Changes 
* TPA treated pouches (right pouch) 
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APPENDIX A 
(vii) 
Summary of the Results of Histologic Evaluation 
1) • The earliest change in epithelial cells was found in 
DMBA/TPA groups at the 3rd week. This was interpreted 
as reactive atypia, and was following recovery from acute 
toxic effect of DMBA. 
2) . Epithelial hyperplasia occurred in both groups within 
first 5 weeks (period I) . 
3). TPA-treated pouches revealed prominent hyperchromasia of 
the epithelium in both experimental and control groups. 
4) • Generally, DMBA/TPA groups revealed prominent 
hyperplastic and atypical changes in pouch epithelium, 
particularly in the third period. Atypia at this stage 
was interpreted de novo, in contrast to period I, and 
independent of cytotoxic reaction by DMBA. Such atypia 
was not expressed in TPA alone treated epithelia. 
* Note: Grossly, by the end of the 13th week, there was 
neither papilloma or tumor growth in this 
experiment. 
APPENDIX B 
Table I: lllllaM'lOStaining of RAP-5 anti-ras p21 
wk 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
Left CA) - + + ++ + ++ 
DM8A 
+TPA (8) - + +/- +/- +/- + + +/- + 
Right CA) +/- + + +/- +/- + 
TPA (8) +/- + + 
Note: +++ strong reaction 
++ moderate reaction 
+ weak reaction 
+/- occasionally weak reaction 
negative reaction 
++ ++ ++ ++ 
+ + + 
+/- +/-
+ + +/-
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Table II: lllllll'lOStaining of anti TGF-o<. 
wk 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
Left (A) • +/· +/· ++ + +/- +++ ++ + ++ 
DMBA 
+TPA (8) - + + +/- ++ + ++ +/· 
Right (A) +/- +/· ++ 
TPA (8) +/- +/- +/- +/- + +/-
Note: +++ strong reaction 
++ moderate reaction 
+ weak reaction 
+/· occasionally weak reaction 
negative reaction 
Table III: JllllM.»'lOStaining of anti EGF-R 
wk 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
Left (A) + + + + 
DMBA 
+TPA (8) + + +/- + 
Right (A) 
TPA (8) +/- +/-
Note: +++ strong reaction 
++ lllOderate reaction 
+ weak reaction 
+/- occasionally weak reaction 
negative reaction 
+ + 
+ ++ 
++ 
+ ++ + ++ + + 
+ +/- + + ++ + 
+ + 
+ ++ + 
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Time 
(week) 
13th 111111111111111111111 
12th 11111111 
11th 11111111 
10th 11111111 
9th 11111111 
8th 
7th 11111111 
6th 
5th 
4th 
* RAP·S anti·ras p21 
3rd 
2nd c:::::::::::J B h11111Ster pouch 
1st 1111 A hamster pouch 
1--1--1 1--1--1----
(·) (+/-) (+) (++) (+++) Score of the 
Staining 
* 
DMBA + TPA treated pouches Cleft pouch) 
Time 
(week> 
13th 
12th 
11th 
10th 
9th 
8th 
7th 
6th 
5th 
4th 
3rd 
2nd 
1st 
111111111111111111111 
111111111 
c::::J B hamster pouch 
1111 A hamster pouch 
...____, __ , ___ ---1--1--1----
(·) (+/·) (+) (++) (+++) 
* 
DMBA + TPA treated pouches (left pouch) 
Score of the 
Staining 
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Time 
(week) 
13th 
12th 
11th 
10th 
9th 
8th 
7th 
6th 
5th 
4th 
3rd 
2nd 
1st 
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11111111 
* anti EGF-R 
c::::J B hamster pouch 
1111 A hamster pouch 
1--1---1--1--1--1-----
(-) (+/-) (+) (++) (+++) Score of the 
Staining 
* 
DMBA + TPA treated pouches Cleft pouch) 
Time 
(week) 
13th 
12th 
11th 
10th 
9th 
8th 
7th 
6th 
5th 
4th 
3rd 
2nd 
1st 
170 
* RAP-5 anti-ras p21 
c:::::l B hamster pouch 
1111 A hamster pouch 
:--:---:--1--1--1-----
(-) (+/-) (+) (++) (+++) Score of the 
Staining 
* TPA treated pouches (right pouch) 
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Ti!lle 
(week) 
13th 
12th 
11th 
10th 
9th 
8th 
7th 111111111111111 
6th 
5th 
4th 
* anti TGF-o< 
3rd 
111111 
2nd c:::::J B hamster pouch 
1st 1111 A hamster pouch 
'---1--1---:--1--1--1-----
(·) (+/·) (+) (++) (+++) Score of the 
Staining 
* 
TPA treated pouches (right pouch) 
Time 
(week) 
13th 
12th 
11th 
10th 
9th 
8th 
7th 
6th 
5th 
4th 
3rd 
2nd 
1st 
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111111111111111111111 
* anti EGF-R 
c:::J B hamster pouch 
1111 A hamster pouch 
1--1---1--1--1--1-----
(-) (+/·) (+) (++) (+++) Score of the 
Staining 
* 
TPA treated pouches (right pouch) 
APPENDIX C 
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APPENDIX C 
Statistical Analysis of the Im:munoreactivity of RAP-5anti-ras 
p21 antiTGF- 0( and antiEGF-R 
"Two Sample T test" is used in this statistical analysis to 
conclude whether there is statistically significant difference 
between the experimental DMBA/TPA treated groups and TPA alone 
treated groups, or not. This method can also be considered 
as an extension of the "analysis of variance" (one way block) 
which actually works with the "squares of the deviation" 
instead of "square roots of the variances". 
In order to analyze the grading system (-, +/-, +, ++, +++) 
that we used for the im:munostaining of these three antibodies, 
we give a serial of numbers (2,4,6,8,10 respectively) for the 
scores. It does not have to be this set of numbers. Any 
other serial of numbers also work perfectly with this 
statistical analysis. 
i). RAP-5anti-ras p21: 
After the replacement of the grading system with numbers 
and putting A scores and B scores together in each 
groups, we have the following scores of left and right 
pouches for RAP-5anti-ras p21. (Original grading is in 
Appendix B table I.) 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
L 4 8 10 6 10 8 14 10 14 14 14 14 10 
R 6 8 4 8 6 10 6 12 10 10 6 4 
The Null Hypothesis (Ho) is that: 
If UL = UR, 
there is no significant difference between the left 
and right pouches. Otherwise, we have to reject the 
Ho. And, there is significant difference between 
the left and right pouches. 
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XL = sum of the scores of left pouches = 136 
NL = total samples of left pouches = 13 
-XL = mean of the scores of left pouches = 136/13 
x 2 -L - 42 + 82 + 102 + 62 + 102 + 82 + 142 + 
102 + 142 + 142 + 142 + 142 + 102 
= 1560 
~ = sum of the scores of right pouches = 90 
NR = total samples of right pouches = 12 
XR = mean of the scores of right pouches = 90/12 
XR2 = 62 + 82 + 42 + 82 + 62 + 102 + 62 + 
122 + 102 + 102 + 62 + 4 2 
= 748 
"two s~le T test 11 
= 
= 
= 
= 
[(N1 - 1>s,2 + <N2 - 1)S22J 
(N1 + N2 - 2) 
- 2 - 2 <X1 - X1> + <X2 - X2> 
N1 + N2 - 2 
N2 - 1 
p (at 
* 
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X1 - Xz X1 - Xz 
t = = S/F ITT s I 2 
[1560 
-
(136) 2/13] + [748 - (90) 2/12] 
s2P = 
13 + 12 - 2 
= 9.1404682 
s = JsP2 =J 9.1404682 = 3.0233207 
136/13 - 90/12 
t = 
3. 0233207 J 1/ 13 + 1/ 12 
= 2.4469522 
df = NL + NR - 2 = 13 + 12 - 2 = 23 
= degree of freedom 
Check the P values for different T and dt in the t Table. 
dt 
p --> 0.05 0.02 0.01 
23 2.07 2.50 2.81 
0.05) < t (=2.4469522) < p (at 0.02) 
We set p (OC. value) at 0.05 (5%) • 
So, we reject the Ho. 
And, we can conclude that there is statistically 
significant difference between left pouches (DMBA/TPA) 
and right pouches (TPA alone) for RAP-5anti-ras p21. 
ii) • antiTGF-o(: 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
L 4 4 4 4 10 10 12 14 10 18 10 10 10 
R 6 8 4 4 8 12 4 8 6 4 4 4 
XL = 120 ~ = 72 
NL = 13 NR = 12 
XL = 120/13 ~ = 72/12 = 6 
XL2 = 1328 ~2= 504 
(1328 - (120) 2/13] + (504 - (72) 2/12] 
13 + 12 - 2 
= 12.70903 
s = Jsp2 = 3.5649726 
120/13 - 6 
t = 
3. 5649726 J l/ 13 
df = 13 + 12 - 2 = 23 
Check the t Table. 
p --> 
23 
+ 1/12 
0.05 
2.07 
= 2.2638212 
0.02 
2.50 
0.01 
2.81 
P (at 0.05) < t (=2.2638212) < P (at 0.02) 
* we set P ( c< value) at o. 05 (5%) • 
So, we reject the Ho. 
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And, we can conclude that there is statistically 
significant difference between left pouches (DMBA/TPA) 
and right pouches (TPA alone) for antiTGF-OC. 
iii).antiEGF-R: 
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
L 14 8 8 10 12 12 14 12 12 12 14 14 12 
R 4 4 6 6 4 10 4 12 4 8 10 8 
XL = 
NL = 
XL = 
xL2 = 
154 
13 
154/13 
1876 
Xa = 80 
NR = 12 
Xa = 80/12 
X.,2= 624 
[1876 -
s2P (154)
2/13] + [624 - (80) 2/12] 
= 
13 + 12 - 2 
= 6.1895247 
s =P = 6.1895247 = 
120/13 - 6 
t = 
2. 4878755 j 1/ 13 
Check the t Table. 
p --> 
23 
2.4878755 
+ 1/12 
0.05 
2.27 
P (at 0.05) << t (=5.2005648) 
* we set P Co<.value> at 0.05 (5%). 
So, we reject the Ho. 
= 5.2005648 
0.02 
2.50 
0.01 
2.81 
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And, we can conclude that there is statistically 
significant difference between left pouches (DMBA/TPA) 
and right pouches (TPA alone) for antiEGF-R. 
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